# Gareth Evans

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6454656/publications.pdf

Version: 2024-02-01

| 1,004 | 86,902 | 426 | 748 |
|---|---|---|---|
| papers | citations | 136 h-index | 256 g-index |

| 1056 | 1056 | 1056 | 57995 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies. American Journal of Human Genetics, 2003, 72, 1117-1130. | 2.6 | 3,105 |
| 2 | Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 2007, 447, 1087-1093. | 13.7 | 2,165 |
| 3 | Replication of Genome-Wide Association Signals in UK Samples Reveals Risk Loci for Type 2 Diabetes. Science, 2007, 316, 1336-1341. | 6.0 | 2,040 |
| 4 | Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA - Journal of the American Medical Association, 2017, 317, 2402. | 3.8 | 1,898 |
| 5 | Prophylactic Oophorectomy in Carriers ofBRCA1orBRCA2Mutations. New England Journal of Medicine, 2002, 346, 1616-1622. | 13.9 | 1,565 |
| 6 | Association of Risk-Reducing Surgery in <emph type="ital">BRCA1</emph> or <emph type="ital">BRCA2</emph> Mutation Carriers With Cancer Risk and Mortality. JAMA - Journal of the American Medical Association, 2010, 304, 967. | 3.8 | 1,241 |
| 7 | Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group. Journal of Clinical Oncology, 2004, 22, 1055-1062. | 0.8 | 1,095 |
| 8 | Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nature Genetics, 2002, 31, 55-59. | 9.4 | 1,001 |
| 9 | Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut, 2010, 59, 666-689. | 6.1 | 1,000 |
| 10 | PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nature Genetics, 2007, 39, 165-167. | 9.4 | 858 |
| 11 | Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet, The, 2011, 378, 2081-2087. | 6.3 | 849 |
| 12 | Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. Journal of Medical Genetics, 2006, 44, 81-88. | 1.5 | 778 |
| 13 | Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk. New England Journal of Medicine, 2015, 372, 2243-2257. | 13.9 | 764 |
| 14 | Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE. Journal of the National Cancer Institute, 2013, 105, 812-822. | 3.0 | 753 |
| 15 | Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature, 2010, 464, 713-720. | 13.7 | 737 |
| 16 | Birth incidence and prevalence of tumorâ€prone syndromes: Estimates from a UK family genetic register service. American Journal of Medical Genetics, Part A, 2010, 152A, 327-332. | 0.7 | 721 |
| 17 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34. | 2.6 | 711 |
| 18 | Genome-wide association study identifies five new breast cancer susceptibility loci. Nature Genetics, 2010, 42, 504-507. | 9.4 | 653 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nature Genetics, 2006, 38, 873-875. | 9.4 | 641 |
| 20 | Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer. Journal of Clinical Oncology, 2013, 31, 1748-1757. | 0.8 | 641 |
| 21 | Identification of the familial cylindromatosis tumour-suppressor gene. Nature Genetics, 2000, 25, 160-165. | 9.4 | 640 |
| 22 | Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nature Genetics, 2006, 38, 1239-1241. | 9.4 | 636 |
| 23 | Oral Contraceptives and the Risk of Hereditary Ovarian Cancer. New England Journal of Medicine, 1998, 339, 424-428. | 13.9 | 591 |
| 24 | Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype. Clinical Cancer Research, 2005, 11, 5175-5180. | 3.2 | 577 |
| 25 | The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. International Journal of Obesity, 2011, 35, 714-727. | 1.6 | 573 |
| 26 | Association Between <emph type="ital">BRCA1</emph> and <emph type="ital">BRCA2</emph> Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer. JAMA - Journal of the American Medical Association, 2012, 307, 382. | 3.8 | 546 |
| 27 | Breast Cancer Risk Genes â€" Association Analysis in More than 113,000 Women. New England Journal of Medicine, 2021, 384, 428-439. | 13.9 | 532 |
| 28 | Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study. Journal of Clinical Oncology, 2008, 26, 1331-1337. | 0.8 | 522 |
| 29 | A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nature Genetics, 2008, 40, 623-630. | 9.4 | 514 |
| 30 | Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 134-147. | 1.1 | 513 |
| 31 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384. | 9.4 | 493 |
| 32 | Complications of the naevoid basal cell carcinoma syndrome: results of a population based study.. Journal of Medical Genetics, 1993, 30, 460-464. | 1.5 | 485 |
| 33 | Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotypeâ€"phenotype correlation. Nature Genetics, 1995, 11, 428-433. | 9.4 | 484 |
| 34 | The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. British Journal of Cancer, 2008, 98, 1457-1466. | 2.9 | 461 |
| 35 | Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nature Genetics, 2011, 43, 879-882. | 9.4 | 460 |
| 36 | Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nature Genetics, 2009, 41, 585-590. | 9.4 | 434 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity.. Journal of Medical Genetics, 1992, 29, 841-846. | 1.5 | 421 |
| 38 | Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH. Lancet, The, 2003, 362, 39-41. | 6.3 | 421 |
| 39 | Assessing Women at High Risk of Breast Cancer: A Review of Risk Assessment Models. Journal of the National Cancer Institute, 2010, 102, 680-691. | 3.0 | 413 |
| 40 | Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut, 2017, 66, 464-472. | 6.1 | 411 |
| 41 | Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene, 2001, 20, 4621-4628. | 2.6 | 410 |
| 42 | Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut, 2018, 67, 1306-1316. | 6.1 | 410 |
| 43 | Neurofibromatosis type 2 (NF2): A clinical and molecular review. Orphanet Journal of Rare Diseases, 2009, 4, 16. | 1.2 | 404 |
| 44 | Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group. Journal of Clinical Oncology, 2005, 23, 7804-7810. | 0.8 | 396 |
| 45 | Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347. | 3.8 | 390 |
| 46 | Allele losses in the region 17q12â€“21 in familial breast and ovarian cancer involve the wildâ€“type chromosome. Nature Genetics, 1992, 2, 128-131. | 9.4 | 387 |
| 47 | Location of gene for Gorlin syndrome. Lancet, The, 1992, 339, 581-582. | 6.3 | 382 |
| 48 | Diagnostic criteria for schwannomatosis. Neurology, 2005, 64, 1838-1845. | 1.5 | 368 |
| 49 | Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genetics in Medicine, 2020, 22, 15-25. | 1.1 | 365 |
| 50 | Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clinical Cancer Research, 2017, 23, e38-e45. | 3.2 | 358 |
| 51 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691. | 9.4 | 356 |
| 52 | A clinical study of type 2 neurofibromatosis. The Quarterly Journal of Medicine, 1992, 84, 603-18. | 1.0 | 348 |
| 53 | Whole-genome sequencing of patients with rare diseases in a national health system. Nature, 2020, 583, 96-102. | 13.7 | 338 |
| 54 | The effect of intermittent energy and carbohydrate restrictionv. daily energy restriction on weight loss and metabolic disease risk markers in overweight women. British Journal of Nutrition, 2013, 110, 1534-1547. | 1.2 | 336 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | An Absence of Cutaneous Neurofibromas Associated with a 3-bp Inframe Deletion in Exon 17 of the NF1 Gene (c.2970-2972 delAAT): Evidence of a Clinically Significant NF1 Genotype-Phenotype Correlation. American Journal of Human Genetics, 2007, 80, 140-151. | 2.6 | 335 |
| 56 | Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nature Genetics, 2010, 42, 973-977. | 9.4 | 335 |
| 57 | Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncology, The, 2006, 7, 223-229. | 5.1 | 333 |
| 58 | Incidence of Vestibular Schwannoma and Neurofibromatosis 2 in the North West of England over a 10-year Period: Higher Incidence than Previously Thought. Otology and Neurotology, 2005, 26, 93-97. | 0.7 | 328 |
| 59 | Tumor risks and genotypeÃ¢Â€Â“phenotypeÃ¢Â€Â“proteotype analysis in 358 patients with germline mutations inSDHBandSDHD. Human Mutation, 2010, 31, 41-51. | 1.1 | 325 |
| 60 | Li-Fraumeni syndrome â€“ a molecular and clinical review. British Journal of Cancer, 1997, 76, 1-14. | 2.9 | 324 |
| 61 | Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research, 2013, 15, R92. | 2.2 | 320 |
| 62 | Second Primary Tumors in Neurofibromatosis 1 Patients Treated for Optic Glioma: Substantial Risks After Radiotherapy. Journal of Clinical Oncology, 2006, 24, 2570-2575. | 0.8 | 319 |
| 63 | Oral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2002, 94, 1773-1779. | 3.0 | 318 |
| 64 | Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncology, The, 2018, 19, 169-180. | 5.1 | 316 |
| 65 | Germline E-cadherin Gene (CDH1) Mutations Predispose to Familial Gastric Cancer and Colorectal Cancer. Human Molecular Genetics, 1999, 8, 607-610. | 1.4 | 312 |
| 66 | A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptorâ€“negative breast cancer in the general population. Nature Genetics, 2010, 42, 885-892. | 9.4 | 309 |
| 67 | Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genetics in Medicine, 2021, 23, 1506-1513. | 1.1 | 290 |
| 68 | The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma. British Journal of Cancer, 1991, 64, 959-961. | 2.9 | 284 |
| 69 | Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clinical Genetics, 2009, 75, 141-149. | 1.0 | 280 |
| 70 | Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. European Urology, 2015, 68, 186-193. | 0.9 | 279 |
| 71 | Psychosocial impact of breast/ovarian (BRCA 1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort. British Journal of Cancer, 2004, 91, 1787-1794. | 2.9 | 276 |
| 72 | Effect of Aspirin or Resistant Starch on Colorectal Neoplasia in the Lynch Syndrome. New England Journal of Medicine, 2008, 359, 2567-2578. | 13.9 | 273 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. Journal of Clinical Oncology, 2020, 38, 674-685. | 0.8 | 270 |
| 74 | Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581. | 9.4 | 265 |
| 75 | Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. Journal of Medical Genetics, 2003, 40, 807-814. | 1.5 | 261 |
| 76 | Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. American Journal of Human Genetics, 2008, 82, 937-948. | 2.6 | 257 |
| 77 | Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Familial Cancer, 2012, 11, 235-242. | 0.9 | 252 |
| 78 | The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Research, 2014, 16, 442. | 2.2 | 252 |
| 79 | Risk determination and prevention of breast cancer. Breast Cancer Research, 2014, 16, 446. | 2.2 | 248 |
| 80 | Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212. | 1.5 | 244 |
| 81 | Are There Low-Penetrance TP53 Alleles? Evidence from Childhood Adrenocortical Tumors. American Journal of Human Genetics, 1999, 65, 995-1006. | 2.6 | 240 |
| 82 | Germline SDHD mutation in familial phaeochromocytoma. Lancet, The, 2001, 357, 1181-1182. | 6.3 | 236 |
| 83 | Germline Mutations in SUFU Cause Gorlin Syndromeâ€“Associated Childhood Medulloblastoma and Redefine the Risk Associated With PTCH1 Mutations. Journal of Clinical Oncology, 2014, 32, 4155-4161. | 0.8 | 236 |
| 84 | A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. Journal of Medical Genetics, 2004, 41, 474-480. | 1.5 | 232 |
| 85 | Management of the patient and family with neurofibromatosis 2: a consensus conference statement. British Journal of Neurosurgery, 2005, 19, 5-12. | 0.4 | 229 |
| 86 | Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620. | 1.1 | 224 |
| 87 | Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet, The, 2020, 395, 1855-1863. | 6.3 | 220 |
| 88 | Germline RAD51C mutations confer susceptibility to ovarian cancer. Nature Genetics, 2012, 44, 475-476. | 9.4 | 219 |
| 89 | Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature, 2013, 493, 406-410. | 13.7 | 218 |
| 90 | A genetic register for von Hippel-Lindau disease.. Journal of Medical Genetics, 1996, 33, 120-127. | 1.5 | 215 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology, 2002, 59, 1759-1765. | 1.5 | 215 |
| 92 | Predictors of the Risk of Mortality in Neurofibromatosis 2. American Journal of Human Genetics, 2002, 71, 715-723. | 2.6 | 211 |
| 93 | Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Nature Genetics, 2013, 45, 295-298. | 9.4 | 208 |
| 94 | Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet, The, 2003, 361, 1101-1102. | 6.3 | 200 |
| 95 | Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Research, 1997, 57, 3245-52. | 0.4 | 198 |
| 96 | Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. Journal of Medical Genetics, 2007, 44, 481-484. | 1.5 | 196 |
| 97 | Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology, 2014, 66, 489-499. | 0.9 | 195 |
| 98 | A Randomized Placebo-Controlled Prevention Trial of Aspirin and/or Resistant Starch in Young People with Familial Adenomatous Polyposis. Cancer Prevention Research, 2011, 4, 655-665. | 0.7 | 193 |
| 99 | Pregnancies, Breast-Feeding, and Breast Cancer Risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). Journal of the National Cancer Institute, 2006, 98, 535-544. | 3.0 | 191 |
| 100 | Penetrance estimates for BRCA1 and BRCA2based on genetic testing in a Clinical Cancer Genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer, 2008, 8, 155. | 1.1 | 191 |
| 101 | Frequent hSNF5/INI1 Germline Mutations in Patients with Rhabdoid Tumor. Clinical Cancer Research, 2011, 17, 31-38. | 3.2 | 191 |
| 102 | EANO guideline on the diagnosis and treatment of vestibular schwannoma. Neuro-Oncology, 2020, 22, 31-45. | 0.6 | 190 |
| 103 | Effect of Chest X-Rays on the Risk of Breast Cancer Among BRCA1/2 Mutation Carriers in the International BRCA1/2 Carrier Cohort Study: A Report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaboratorsâ€™ Group. Journal of Clinical Oncology, 2006, 24, 3361-3366. | 0.8 | 188 |
| 104 | Heritability of Cellular Radiosensitivity: A Marker of Low-Penetrance Predisposition Genes in Breast Cancer?. American Journal of Human Genetics, 1999, 65, 784-794. | 2.6 | 186 |
| 105 | Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ, The, 2012, 345, e5660-e5660. | 3.0 | 186 |
| 106 | Cancer risk in Lynch Syndrome. Familial Cancer, 2013, 12, 229-240. | 0.9 | 186 |
| 107 | Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort. Breast Cancer Research, 2015, 17, 147. | 2.2 | 186 |
| 108 | Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations.. Journal of Medical Genetics, 1998, 35, 450-455. | 1.5 | 185 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Cancer phenotype correlates with constitutional TP53 genotype in families with the Liâ€“Fraumeni syndrome. Oncogene, 1998, 17, 1061-1068. | 2.6 | 180 |
| 110 | Paediatric presentation of type 2 neurofibromatosis. Archives of Disease in Childhood, 1999, 81, 496-499. | 1.0 | 180 |
| 111 | Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. Journal of Medical Genetics, 2008, 45, 332-339. | 1.5 | 179 |
| 112 | Germline selection shapes human mitochondrial DNA diversity. Science, 2019, 364, . | 6.0 | 178 |
| 113 | Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nature Reviews Clinical Oncology, 2020, 17, 687-705. | 12.5 | 178 |
| 114 | Predictive testing for BRCA1/2: attributes, risk perception and management in a multi-centre clinical cohort. British Journal of Cancer, 2002, 86, 1209-1216. | 2.9 | 173 |
| 115 | Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction. Cancer Research, 2010, 70, 9742-9754. | 0.4 | 169 |
| 116 | The impact of genetic counselling on risk perception in women with a family history of breast cancer. British Journal of Cancer, 1994, 70, 934-938. | 2.9 | 168 |
| 117 | Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. Journal of Medical Genetics, 2008, 45, 425-431. | 1.5 | 167 |
| 118 | Guidelines for the Liâ€“Fraumeni and heritable TP53-related cancer syndromes. European Journal of Human Genetics, 2020, 28, 1379-1386. | 1.4 | 167 |
| 119 | Neuroimaging manifestations in children with SARS-CoV-2 infection: a multinational, multicentre collaborative study. The Lancet Child and Adolescent Health, 2021, 5, 167-177. | 2.7 | 166 |
| 120 | Neurofibromatosis type 2. Journal of Medical Genetics, 2000, 37, 897-904. | 1.5 | 165 |
| 121 | Perception of risk in women with a family history of breast cancer. British Journal of Cancer, 1993, 67, 612-614. | 2.9 | 162 |
| 122 | Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989. European Journal of Human Genetics, 2011, 19, 1187-1191. | 1.4 | 161 |
| 123 | Bilateral Oophorectomy and Breast Cancer Risk inBRCA1andBRCA2Mutation Carriers. Journal of the National Cancer Institute, 2017, 109, . | 3.0 | 160 |
| 124 | The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome. Genetics in Medicine, 2019, 21, 2390-2400. | 1.1 | 153 |
| 125 | Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250. | 0.8 | 152 |
| 126 | Screening for Familial Ovarian Cancer: Failure of Current Protocols to Detect Ovarian Cancer at an Early Stage According to the International Federation of Gynecology and Obstetrics System. Journal of Clinical Oncology, 2005, 23, 5588-5596. | 0.8 | 151 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Autism and other psychiatric comorbidity in neurofibromatosis type 1: evidence from a populationâ€based study. Developmental Medicine and Child Neurology, 2013, 55, 139-145. | 1.1 | 149 |
| 128 | Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging. JAMA Oncology, 2017, 3, 1634. | 3.4 | 148 |
| 129 | Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. Journal of Clinical Oncology, 2017, 35, 1411-1420. | 0.8 | 148 |
| 130 | Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. European Urology, 2019, 76, 831-842. | 0.9 | 148 |
| 131 | Whole-genome sequencing of a sporadic primary immunodeficiency cohort. Nature, 2020, 583, 90-95. | 13.7 | 148 |
| 132 | High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH. Human Molecular Genetics, 2001, 10, 271-282. | 1.4 | 147 |
| 133 | Familial Breast Cancer. Clinical Genetics, 2012, 82, 105-114. | 1.0 | 147 |
| 134 | A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling.. Journal of Medical Genetics, 1992, 29, 847-852. | 1.5 | 146 |
| 135 | Neurofibromatosis Type 1 and Autism Spectrum Disorder. Pediatrics, 2013, 132, e1642-e1648. | 1.0 | 145 |
| 136 | Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. Journal of Medical Genetics, 2007, 44, 424-428. | 1.5 | 144 |
| 137 | Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Cancer Research and Treatment, 2013, 140, 135-142. | 1.1 | 144 |
| 138 | Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844â€“848. American Journal of Human Genetics, 2018, 102, 69-87. | 2.6 | 144 |
| 139 | Increasing the specificity of diagnostic criteria for schwannomatosis. Neurology, 2006, 66, 730-732. | 1.5 | 143 |
| 140 | Breast cancer risk-assessment models. Breast Cancer Research, 2007, 9, 213. | 2.2 | 142 |
| 141 | Genotype-Phenotype Correlations for Nervous System Tumors in Neurofibromatosis 2: A Population-Based Study. American Journal of Human Genetics, 2004, 75, 231-239. | 2.6 | 140 |
| 142 | BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. European Journal of Cancer, 2006, 42, 1143-1150. | 1.3 | 139 |
| 143 | Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome. Clinical Cancer Research, 2017, 23, e62-e67. | 3.2 | 139 |
| 144 | The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis. Genetics in Medicine, 2019, 21, 2167-2180. | 1.1 | 139 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Loss of SUFU Function in Familial Multiple Meningioma. American Journal of Human Genetics, 2012, 91, 520-526. | 2.6 | 137 |
| 146 | A clinical study of type 1 neurofibromatosis in north west England. Journal of Medical Genetics, 1999, 36, 197-203. | 1.5 | 137 |
| 147 | Neurofibromatosis type 1 and sporadic optic gliomas. Archives of Disease in Childhood, 2002, 87, 65-70. | 1.0 | 135 |
| 148 | Familial infiltrative fibromatosis (desmoid tumours) (MIM135290) caused by a recurrent 3' APC gene mutation. Human Molecular Genetics, 1996, 5, 1921-1924. | 1.4 | 134 |
| 149 | MRI breast screening in high-risk women: cancer detection and survival analysis. Breast Cancer Research and Treatment, 2014, 145, 663-672. | 1.1 | 133 |
| 150 | Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1. Clinical Cancer Research, 2017, 23, e46-e53. | 3.2 | 133 |
| 151 | Uptake of Risk-Reducing Surgery in Unaffected Women at High Risk of Breast and Ovarian Cancer Is Risk, Age, and Time Dependent. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2318-2324. | 1.1 | 132 |
| 152 | Assessment of in vitro sperm characteristics in relation to fertility in dairy bulls. Animal Reproduction Science, 2008, 103, 201-214. | 0.5 | 131 |
| 153 | Reproductive and Hormonal Factors, and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 601-610. | 1.1 | 130 |
| 154 | European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender. British Journal of Surgery, 2021, 108, 484-498. | 0.1 | 130 |
| 155 | Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet, The, 2020, 395, 117-122. | 6.3 | 128 |
| 156 | Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database. Gut, 2017, 66, 1657-1664. | 6.1 | 127 |
| 157 | Results of Annual Screening in Phase I of the United Kingdom Familial Ovarian Cancer Screening Study Highlight the Need for Strict Adherence to Screening Schedule. Journal of Clinical Oncology, 2013, 31, 49-57. | 0.8 | 126 |
| 158 | Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome. JAMA Oncology, 2017, 3, 1702. | 3.4 | 125 |
| 159 | Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring. Journal of Medical Genetics, 2003, 40, 459-463. | 1.5 | 124 |
| 160 | Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. European Urology, 2020, 77, 24-35. | 0.9 | 124 |
| 161 | Clinical follow-up after bilateral risk reducing (?prophylactic?) mastectomy: mental health and body image outcomes. Psycho-Oncology, 2000, 9, 462-472. | 1.0 | 121 |
| 162 | Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. Journal of Medical Genetics, 2005, 42, 602-603. | 1.5 | 121 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Life expectancy in hereditary cancer predisposing diseases: an observational study. Journal of Medical Genetics, 2012, 49, 264-269. | 1.5 | 121 |
| 164 | Neurofibromatosis 2, radiosurgery and malignant nervous system tumours. British Journal of Cancer, 2000, 82, 998-998. | 2.9 | 120 |
| 165 | Germline mutation of ARF in a melanoma kindred. Human Molecular Genetics, 2002, 11, 1273-1279. | 1.4 | 120 |
| 166 | Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]. Genetics in Medicine, 2009, 11, 599-610. | 1.1 | 120 |
| 167 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73. | 9.4 | 120 |
| 168 | Variants in CHEK2 Other than 1100delC Do Not Make a Major Contribution to Breast Cancer Susceptibility. American Journal of Human Genetics, 2003, 72, 1023-1028. | 2.6 | 119 |
| 169 | Mammographic Density and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Research, 2006, 66, 1866-1872. | 0.4 | 119 |
| 170 | Cancer risk and genotypeâ€“phenotype correlations in PTEN hamartoma tumor syndrome. Familial Cancer, 2014, 13, 57-63. | 0.9 | 119 |
| 171 | The gene for the naevoid basal cell carcinoma syndrome acts as a tumour-suppressor gene in medulloblastoma. British Journal of Cancer, 1997, 76, 141-145. | 2.9 | 118 |
| 172 | Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. British Journal of Cancer, 2010, 103, 918-924. | 2.9 | 118 |
| 173 | Analysis of genetic and phenotypic heterogeneity in juvenile polyposis. Gut, 2000, 46, 656-660. | 6.1 | 117 |
| 174 | Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. Journal of Medical Genetics, 2009, 46, 593-597. | 1.5 | 116 |
| 175 | Increased Colorectal Cancer Incidence in Obligate Carriers of Heterozygous Mutations in MUTYH. Gastroenterology, 2009, 137, 489-494.e1. | 0.6 | 114 |
| 176 | Frequency of SMARCB1 mutations in familial and sporadic schwannomatosis. Neurogenetics, 2012, 13, 141-145. | 0.7 | 114 |
| 177 | Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer. British Journal of Cancer, 2006, 95, 801-810. | 2.9 | 113 |
| 178 | A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes and Cancer, 2006, 45, 646-655. | 1.5 | 111 |
| 179 | Schwannomatosis: a genetic and epidemiological study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1215-1219. | 0.9 | 111 |
| 180 | Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk Prediction. JAMA Oncology, 2018, 4, 476. | 3.4 | 109 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Germline <scp>SMARCE1</scp> mutations predispose to both spinal and cranial clear cell meningiomas. Journal of Pathology, 2014, 234, 436-440. | 2.1 | 108 |
| 182 | Impaired Tamoxifen Metabolism Reduces Survival in Familial Breast Cancer Patients. Clinical Cancer Research, 2008, 14, 5913-5918. | 3.2 | 107 |
| 183 | Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology, 2013, 81, S33-40. | 1.5 | 107 |
| 184 | Germline mutations in the neurofibromatosis type 2 tumour suppressor gene. Human Molecular Genetics, 1994, 3, 813-816. | 1.4 | 106 |
| 185 | Guidelines for a genetic risk based approach to advising women with a family history of breast cancer. Journal of Medical Genetics, 2000, 37, 203-209. | 1.5 | 106 |
| 186 | Neurofibromatosis 2. Current Opinion in Neurology, 2003, 16, 27-33. | 1.8 | 106 |
| 187 | Germline and somaticNF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs). Human Mutation, 2008, 29, 74-82. | 1.1 | 106 |
| 188 | The Fragile X Protein binds m <scp>RNA</scp> s involved in cancer progression and modulates metastasis formation. EMBO Molecular Medicine, 2013, 5, 1523-1536. | 3.3 | 106 |
| 189 | Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Journal of Cancer, 1998, 34, 1922-1926. | 1.3 | 105 |
| 190 | Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. PLoS Genetics, 2013, 9, e1003173. | 1.5 | 105 |
| 191 | Psychological support needs for women at high genetic risk of breast cancer: some preliminary indicators. , 1998, 7, 402-412. | | 104 |
| 192 | Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. Magnetic Resonance Imaging, 2000, 18, 765-776. | 1.0 | 104 |
| 193 | The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians. Cancer Cell, 2011, 19, 273-282. | 7.7 | 104 |
| 194 | Assessing Individual Breast Cancer Risk within the U.K. National Health Service Breast Screening Program: A New Paradigm for Cancer Prevention. Cancer Prevention Research, 2012, 5, 943-951. | 0.7 | 104 |
| 195 | Systematic review of the impact of registration and screening on colorectal cancer incidence and mortality in familial adenomatous polyposis and Lynch syndrome. British Journal of Surgery, 2013, 100, 1719-1731. | 0.1 | 104 |
| 196 | Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1 -related schwannomatosis. Neurology, 2017, 88, 87-92. | 1.5 | 104 |
| 197 | Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening. Journal of Medical Genetics, 2006, 44, 10-15. | 1.5 | 102 |
| 198 | A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. Journal of Medical Genetics, 2010, 47, 771-774. | 1.5 | 102 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. Human Mutation, 2019, 40, 1557-1578. | 1.1 | 102 |
| 200 | Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset. Journal of Medical Genetics, 2011, 48, 261-265. | 1.5 | 101 |
| 201 | Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. American Journal of Medical Genetics, Part A, 2012, 158A, 24-41. | 0.7 | 101 |
| 202 | Risk perception and cancer worry: an exploratory study of the impact of genetic risk counselling in women with a family history of breast cancer. Journal of Medical Genetics, 2001, 38, 139-139. | 1.5 | 100 |
| 203 | Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics,BRCAmutations and oophorectomy. International Journal of Cancer, 2002, 101, 555-559. | 2.3 | 99 |
| 204 | Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2009, 18, 4442-4456. | 1.4 | 99 |
| 205 | Basal Cell Carcinomas in Gorlin Syndrome: A Review of 202 Patients. Journal of Skin Cancer, 2011, 2011, 1-6. | 0.5 | 99 |
| 206 | Characterising the loss-of-function impact of 5â€™ untranslated region variants in 15,708 individuals. Nature Communications, 2020, 11, 2523. | 5.8 | 99 |
| 207 | A detailed study of loss of heterozygosity on chromosome 17 in tumours from Liâ€‰â€“â€‰Fraumeni patients carrying a mutation to the TP53 gene. Oncogene, 1997, 14, 865-871. | 2.6 | 98 |
| 208 | Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another. Cancer, 2001, 92, 959-968. | 2.0 | 98 |
| 209 | The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2. Journal of Medical Genetics, 2005, 42, 540-546. | 1.5 | 98 |
| 210 | Risk of breast cancer in male BRCA2 carriers. Journal of Medical Genetics, 2010, 47, 710-711. | 1.5 | 98 |
| 211 | Human in vivo and in vitro studies on gastrointestinal absorption of titanium dioxide nanoparticles. Toxicology Letters, 2015, 233, 95-101. | 0.4 | 98 |
| 212 | Genetic analysis of mitochondrial complex II subunits SDHD , SDHB and SDHC in paraganglioma and phaeochromocytoma susceptibility. Clinical Endocrinology, 2003, 59, 728-733. | 1.2 | 97 |
| 213 | Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Research, 2014, 16, 3419. | 2.2 | 97 |
| 214 | Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet Oncology, The, 2012, 13, 1242-1249. | 5.1 | 95 |
| 215 | Further genotype â€“ phenotype correlations in neurofibromatosis 2. Clinical Genetics, 2010, 77, 163-170. | 1.0 | 94 |
| 216 | Malignant peripheral nerve sheath tumours in inherited disease. Clinical Sarcoma Research, 2012, 2, 17. | 2.3 | 93 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas. Oncogene, 2010, 29, 6216-6221. | 2.6 | 91 |
| 218 | Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer. PLoS Biology, 2011, 9, e1001199. | 2.6 | 91 |
| 219 | Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study. Journal of Clinical Oncology, 2015, 33, 3591-3597. | 0.8 | 91 |
| 220 | Cancer Screening Recommendations and Clinical Management of Inherited Gastrointestinal Cancer Syndromes in Childhood. Clinical Cancer Research, 2017, 23, e107-e114. | 3.2 | 91 |
| 221 | A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer. JAMA Oncology, 2019, 5, 1718. | 3.4 | 91 |
| 222 | A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations. Journal of Medical Genetics, 2011, 48, 256-260. | 1.5 | 90 |
| 223 | Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis. Neurology, 2015, 84, 141-147. | 1.5 | 90 |
| 224 | Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741. | 5.8 | 90 |
| 225 | Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants. Journal of Clinical Oncology, 2022, 40, 1529-1541. | 0.8 | 90 |
| 226 | Empirical development of improved diagnostic criteria for neurofibromatosis 2. Genetics in Medicine, 2011, 13, 576-581. | 1.1 | 89 |
| 227 | Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15. | 2.2 | 88 |
| 228 | Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431. | 5.8 | 88 |
| 229 | Genetic Severity Score predicts clinical phenotype in NF2. Journal of Medical Genetics, 2017, 54, 657-664. | 1.5 | 87 |
| 230 | Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. The Lancet Gastroenterology and Hepatology, 2018, 3, 489-498. | 3.7 | 87 |
| 231 | Surveillance for familial breast cancer: Differences in outcome according toBRCA mutation status. International Journal of Cancer, 2007, 121, 1017-1020. | 2.3 | 86 |
| 232 | Contribution of cyclin d1 (CCND1) and E-cadherin (CDH1) polymorphisms to familial and sporadic colorectal cancer. Oncogene, 2002, 21, 1928-1933. | 2.6 | 85 |
| 233 | Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. Clinical Genetics, 2008, 74, 233-242. | 1.0 | 85 |
| 234 | Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer. PLoS Genetics, 2010, 6, e1001183. | 1.5 | 85 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. British Journal of Cancer, 2012, 106, 1234-1238. | 2.9 | 85 |
| 236 | Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU International, 2011, 107, 28-39. | 1.3 | 83 |
| 237 | Screening by mammography, women with a family history of breast cancer. European Journal of Cancer, 1998, 34, 937-940. | 1.3 | 82 |
| 238 | Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666. | 1.1 | 82 |
| 239 | Detailed mapping of germline deletions of the von Hippelâ€"Lindau disease tumour suppressor gene. Human Molecular Genetics, 1994, 3, 595-598. | 1.4 | 81 |
| 240 | A Pilot Study of Compositional Analysis of the Breast and Estimation of Breast Mammographic Density Using Three-Dimensional T1-Weighted Magnetic Resonance Imaging. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2268-2274. | 1.1 | 81 |
| 241 | An update on the diagnosis and treatment of vestibular schwannoma. Expert Review of Neurotherapeutics, 2018, 18, 29-39. | 1.4 | 81 |
| 242 | Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. International Journal of Epidemiology, 2019, 48, 795-806. | 0.9 | 81 |
| 243 | Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants. Human Mutation, 2021, 42, 223-236. | 1.1 | 81 |
| 244 | Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. Journal of Medical Genetics, 2009, 46, 811-817. | 1.5 | 80 |
| 245 | Risk reducing mastectomy: outcomes in 10 European centres. Journal of Medical Genetics, 2009, 46, 254-258. | 1.5 | 80 |
| 246 | Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Research and Treatment, 2011, 125, 279-287. | 1.1 | 80 |
| 247 | The accuracy of diagnoses as reported in families with cancer: a retrospective study. Journal of Medical Genetics, 1999, 36, 309-12. | 1.5 | 80 |
| 248 | Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: a clinical and molecular study.. Journal of Neurology, Neurosurgery and Psychiatry, 1997, 62, 361-366. | 0.9 | 79 |
| 249 | Associations of clinical features in neurofibromatosis 1 (NF1). Genetic Epidemiology, 2000, 19, 429-439. | 0.6 | 79 |
| 250 | Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up. British Journal of Cancer, 2007, 96, 718-724. | 2.9 | 79 |
| 251 | Differences in Natural History between Breast Cancers in BRCA1 and BRCA2 Mutation Carriers and Effects of MRI Screening-MRISC, MARIBS, and Canadian Studies Combined. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1458-1468. | 1.1 | 79 |
| 252 | Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers. Breast Cancer Research, 2012, 14, R33. | 2.2 | 78 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients. Journal of Medical Genetics, 2015, 52, 699-705. | 1.5 | 78 |
| 254 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675. | 5.8 | 78 |
| 255 | A Dominantly Inherited 5â€² UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer. American Journal of Human Genetics, 2018, 103, 213-220. | 2.6 | 78 |
| 256 | Bilateral Prophylactic Oophorectomy and Bilateral Prophylactic Mastectomy in a Prospective Cohort of Unaffected BRCA1 and BRCA2 Mutation Carriers. Clinical Breast Cancer, 2007, 7, 875-882. | 1.1 | 77 |
| 257 | Neurofibromatosis/Noonan phenotype: a variable feature of type 1 neurofibromatosis. Clinical Genetics, 1996, 49, 59-64. | 1.0 | 77 |
| 258 | Assessing the usefulness of a novel MRI-based breast density estimation algorithm in a cohort of women at high genetic risk of breast cancer: the UK MARIBS study. Breast Cancer Research, 2009, 11, R80. | 2.2 | 77 |
| 259 | Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: A systematic review. Cancer Treatment Reviews, 2012, 38, 318-328. | 3.4 | 77 |
| 260 | Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. British Journal of Cancer, 2014, 110, 1681-1687. | 2.9 | 77 |
| 261 | Longer term effects of the Angelina Jolie effect: increased risk-reducing mastectomy rates in BRCA carriers and other high-risk women. Breast Cancer Research, 2015, 17, 143. | 2.2 | 77 |
| 262 | A comparison of five methods of measuring mammographic density: a case-control study. Breast Cancer Research, 2018, 20, 10. | 2.2 | 77 |
| 263 | Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders. Clinical Cancer Research, 2017, 23, e54-e61. | 3.2 | 76 |
| 264 | Late Toxicity Is Not Increased in BRCA1/BRCA2 Mutation Carriers Undergoing Breast Radiotherapy in the United Kingdom. Clinical Cancer Research, 2006, 12, 7025-7032. | 3.2 | 75 |
| 265 | BRCACarriers, Prophylactic Salpingo-Oophorectomy and Menopause: Clinical Management Considerations and Recommendations. Women's Health, 2012, 8, 543-555. | 0.7 | 75 |
| 266 | Can Diet and Lifestyle Prevent Breast Cancer: What Is the Evidence?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e66-e73. | 1.8 | 75 |
| 267 | Comparative performances of machine learning methods for classifying Crohn Disease patients using genome-wide genotyping data. Scientific Reports, 2019, 9, 10351. | 1.6 | 75 |
| 268 | Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study. Programme Grants for Applied Research, 2016, 4, 1-210. | 0.4 | 75 |
| 269 | Update on the Manchester Scoring System for BRCA1 and BRCA2 testing. Journal of Medical Genetics, 2005, 42, e39-e39. | 1.5 | 74 |
| 270 | Consensus Recommendations to Accelerate Clinical Trials for Neurofibromatosis Type 2. Clinical Cancer Research, 2009, 15, 5032-5039. | 3.2 | 74 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | Genetic predisposition to peripheral nerve neoplasia: diagnostic criteria and pathogenesis of neurofibromatoses, Carney complex, and related syndromes. Acta Neuropathologica, 2012, 123, 349-367. | 3.9 | 74 |
| 272 | Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 827-831. | 3.3 | 73 |
| 273 | The rs10993994 Risk Allele for Prostate Cancer Results in Clinically Relevant Changes in Microseminoprotein-Beta Expression in Tissue and Urine. PLoS ONE, 2010, 5, e13363. | 1.1 | 73 |
| 274 | Breast cancer risk feedback to women in the UK NHS breast screening population. British Journal of Cancer, 2016, 114, 1045-1052. | 2.9 | 73 |
| 275 | Risk-reducing mastectomy rates in the US: a closer examination of the Angelina Jolie effect. Breast Cancer Research and Treatment, 2018, 171, 435-442. | 1.1 | 73 |
| 276 | Recurrent germline mutation in MSH2 arises frequently de novo. Journal of Medical Genetics, 2000, 37, 646-652. | 1.5 | 72 |
| 277 | Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2011, 13, R110. | 2.2 | 71 |
| 278 | SMARCB1 mutations in schwannomatosis and genotype correlations with rhabdoid tumors. Cancer Genetics, 2014, 207, 373-378. | 0.2 | 71 |
| 279 | Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer. Gynecologic Oncology, 2017, 144, 491-495. | 0.6 | 71 |
| 280 | Fortnightly Review: Familial breast cancer. BMJ: British Medical Journal, 1994, 308, 183-187. | 2.4 | 71 |
| 281 | An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 mutation in TP53.. Journal of Medical Genetics, 1995, 32, 942-945. | 1.5 | 70 |
| 282 | Identification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridisation. Journal of Medical Genetics, 2003, 40, 802-806. | 1.5 | 70 |
| 283 | Apo E genotypes in multiple sclerosis, Parkinson's disease, schwannomas and late-onset Alzheimer's disease. Molecular and Cellular Probes, 1994, 8, 519-525. | 0.9 | 69 |
| 284 | The Genetic Epidemiology of Early-Onset Epithelial Ovarian Cancer: A Population-Based Study. American Journal of Human Genetics, 1999, 65, 1725-1732. | 2.6 | 69 |
| 285 | Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer. Journal of Medical Genetics, 2011, 48, 520-522. | 1.5 | 69 |
| 286 | Familial breast cancer: summary of updated NICE guidance. BMJ, The, 2013, 346, f3829-f3829. | 3.0 | 69 |
| 287 | TumourMLH1promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC). Journal of Medical Genetics, 2014, 51, 789-796. | 1.5 | 69 |
| 288 | Comprehensive RNA Analysis of the NF1 Gene in Classically Affected NF1 Affected Individuals Meeting NIH Criteria has High Sensitivity and Mutation Negative Testing is Reassuring in Isolated Cases With Pigmentary Features Only. EBioMedicine, 2016, 7, 212-220. | 2.7 | 69 |

| # | Article | IF | Citations |
|---|---|---|---|
| 289 | Uptake of genetic testing for cancer predisposition.. Journal of Medical Genetics, 1997, 34, 746-748. | 1.5 | 68 |
| 290 | Characterization of Troponin Responses in Isoproterenol-Induced Cardiac Injury in the Hanover Wistar Rat. Toxicologic Pathology, 2007, 35, 606-617. | 0.9 | 68 |
| 291 | Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2011, 20, 3304-3321. | 1.4 | 68 |
| 292 | Attitudes to reproductive genetic testing in women who had a positive BRCA test before having children: a qualitative analysis. European Journal of Human Genetics, 2012, 20, 4-10. | 1.4 | 68 |
| 293 | Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms. Seminars in Pediatric Neurology, 2015, 22, 240-258. | 1.0 | 68 |
| 294 | Identifying High-Risk Women for Endometrial Cancer Prevention Strategies: Proposal of an Endometrial Cancer Risk Prediction Model. Cancer Prevention Research, 2017, 10, 1-13. | 0.7 | 68 |
| 295 | Cancers inBRCA1andBRCA2Carriers and in Women at High Risk for Breast Cancer: MR Imaging and Mammographic Features. Radiology, 2009, 252, 358-368. | 3.6 | 67 |
| 296 | Parity and breast cancer risk among BRCA1 and BRCA2mutation carriers. Breast Cancer Research, 2006, 8, R72. | 2.2 | 66 |
| 297 | Neurofibromatosis type 2 (NF2). Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 115, 957-967. | 1.0 | 66 |
| 298 | Ipsilateral Cochlear Implantation After Cochlear Nerve Preserving Vestibular Schwannoma Surgery in Patients With Neurofibromatosis Type 2. Otology and Neurotology, 2014, 35, 43-51. | 0.7 | 66 |
| 299 | A common MSH2 mutation in English and North American HNPCC families: origin, phenotypic expression, and sex specific differences in colorectal cancer. Journal of Medical Genetics, 1999, 36, 97-102. | 1.5 | 66 |
| 300 | Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas. Journal of Medical Genetics, 2002, 39, 315-322. | 1.5 | 65 |
| 301 | Spinal tumors in neurofibromatosis Type 2. Is emerging knowledge of genotype predictive of natural history?. Journal of Neurosurgery: Spine, 2005, 2, 574-579. | 0.9 | 65 |
| 302 | Current whole-body MRI applications in the neurofibromatoses. Neurology, 2016, 87, S31-9. | 1.5 | 65 |
| 303 | The Contribution of Whole Gene Deletions and Large Rearrangements to the Mutation Spectrum in Inherited Tumor Predisposing Syndromes. Human Mutation, 2016, 37, 250-256. | 1.1 | 65 |
| 304 | Incidence of mosaicism in 1055 de novo NF2 cases: much higher than previous estimates with high utility of next-generation sequencing. Genetics in Medicine, 2020, 22, 53-59. | 1.1 | 64 |
| 305 | Multiple meningiomas: differential involvement of the NF2 gene in children and adults. Journal of Medical Genetics, 2005, 42, 45-48. | 1.5 | 63 |
| 306 | Colonoscopy screening compliance and outcomes in patients with Lynch syndrome. Colorectal Disease, 2015, 17, 38-46. | 0.7 | 63 |

| # | Article | IF | Citations |
|---|---|---|---|
| 307 | Association of Genetic Predisposition With Solitary Schwannoma or Meningioma in Children and Young Adults. JAMA Neurology, 2017, 74, 1123. | 4.5 | 63 |
| 308 | Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry. American Journal of Obstetrics and Gynecology, 2017, 217, 578.e1-578.e12. | 0.7 | 63 |
| 309 | Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome. European Journal of Human Genetics, 2020, 28, 1387-1393. | 1.4 | 63 |
| 310 | Evaluation of <scp>SDHB</scp>,<scp> SDHD</scp> and <scp>VHL</scp> gene susceptibility testing in the assessment of individuals with nonâ€syndromic phaeochromocytoma, paraganglioma and head and neck paraganglioma. Clinical Endocrinology, 2013, 78, 898-906. | 1.2 | 62 |
| 311 | Reproductive decision-making in young female carriers of a BRCA mutation. Human Reproduction, 2013, 28, 1006-1012. | 0.4 | 62 |
| 312 | Refinement of the basis and impact of common 11q23.1 variation to the risk of developing colorectal cancer. Human Molecular Genetics, 2008, 17, 3720-3727. | 1.4 | 61 |
| 313 | Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer. Menopause International, 2008, 14, 6-12. | 1.6 | 61 |
| 314 | Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds. Journal of Medical Genetics, 2010, 47, 99-102. | 1.5 | 61 |
| 315 | Size and Growth Rate of Sporadic Vestibular Schwannoma: Predictive Value of Information Available at Presentation. Otology and Neurotology, 2005, 26, 86-92. | 0.7 | 60 |
| 316 | Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. British Journal of Cancer, 2011, 105, 22-27. | 2.9 | 60 |
| 317 | Lynch syndrome caused byMLH1mutations is associated with an increased risk of breast cancer: a cohort study. Journal of Medical Genetics, 2015, 52, 553-556. | 1.5 | 60 |
| 318 | Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation. Genetics in Medicine, 2022, 24, 1967-1977. | 1.1 | 60 |
| 319 | Non-Uptake of Predictive Genetic Testing for BRCA1/2 among Relatives of Known Carriers: Attributes, Cancer Worry, and Barriers to Testing in a Multicenter Clinical Cohort. Genetic Testing and Molecular Biomarkers, 2004, 8, 23-29. | 1.7 | 59 |
| 320 | Genetic testing for familial/hereditary breast cancerâ€"comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany. Journal of Community Genetics, 2011, 2, 53-69. | 0.5 | 59 |
| 321 | Inflammation and vascular permeability correlate with growth in sporadic vestibular schwannoma. Neuro-Oncology, 2019, 21, 314-325. | 0.6 | 59 |
| 322 | Mononucleotide microsatellite instability and germline MSH6 mutation analysis in early onset colorectal cancer. Journal of Medical Genetics, 1999, 36, 678-82. | 1.5 | 59 |
| 323 | Men in breast cancer families: a preliminary qualitative study of awareness and experience.. Journal of Medical Genetics, 1998, 35, 739-744. | 1.5 | 58 |
| 324 | Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Research and Treatment, 2010, 124, 195-203. | 1.1 | 58 |

| # | Article | IF | Citations |
|---|---|---|---|
| 325 | Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral. Breast Cancer Research and Treatment, 2013, 142, 611-618. | 1.1 | 58 |
| 326 | PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer. Cancer Chemotherapy and Pharmacology, 2018, 81, 647-658. | 1.1 | 58 |
| 327 | The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study. PLoS Medicine, 2020, 17, e1003263. | 3.9 | 58 |
| 328 | Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. Lancet Oncology, The, 2021, 22, 1014-1022. | 5.1 | 58 |
| 329 | A disease-associated germline deletion maps the type 2 neurofibromatosis (NF2) gene between the Ewing sarcoma region and the leukaemia inhibitory factor locus. Human Molecular Genetics, 1993, 2, 701-704. | 1.4 | 57 |
| 330 | Somatic Mosaicism: A Common Cause of Classic Disease in Tumor-Prone Syndromes? Lessons from Type 2 Neurofibromatosis. American Journal of Human Genetics, 1998, 63, 727-736. | 2.6 | 57 |
| 331 | Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416. | 2.2 | 57 |
| 332 | Uptake of screening and prevention in women at very high risk of breast cancer. Lancet, The, 2001, 358, 889-890. | 6.3 | 56 |
| 333 | Trigeminal schwannomas. British Journal of Neurosurgery, 2008, 22, 729-738. | 0.4 | 56 |
| 334 | Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2014, 148, 397-406. | 1.1 | 56 |
| 335 | Identification of Novel Genetic Markers of Breast Cancer Survival. Journal of the National Cancer Institute, 2015, 107, . | 3.0 | 56 |
| 336 | The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a caseâ€“control study. Journal of Medical Genetics, 2017, 54, 111-113. | 1.5 | 56 |
| 337 | First evidence of genotypeâ€“phenotype correlations in Gorlin syndrome. Journal of Medical Genetics, 2017, 54, 530-536. | 1.5 | 56 |
| 338 | Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants. Breast Cancer Research and Treatment, 2019, 176, 141-148. | 1.1 | 56 |
| 339 | Guidelines for Follow-Up of Women at High Risk for Inherited Breast Cancer: Consensus Statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer. Disease Markers, 1999, 15, 207-211. | 0.6 | 55 |
| 340 | Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set. JAMA Oncology, 2021, 7, 1800. | 3.4 | 55 |
| 341 | Probability of bilateral disease in people presenting with a unilateral vestibular schwannoma. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 66, 764-767. | 0.9 | 54 |
| 342 | Autism Spectrum Disorder Profile in Neurofibromatosis Type I. Journal of Autism and Developmental Disorders, 2015, 45, 1649-1657. | 1.7 | 54 |

| # | Article | IF | Citations |
|---|---|---|---|
| 343 | Type 2 neurofibromatosis: the need for supraregional care?. Journal of Laryngology and Otology, 1993, 107, 401-406. | 0.4 | 53 |
| 344 | Risk assessment and management of high risk familial breast cancer. Journal of Medical Genetics, 2002, 39, 865-871. | 1.5 | 53 |
| 345 | Desmoid tumours in patients with familial adenomatous polyposis and desmoid region adenomatous polyposis coli mutations. British Journal of Surgery, 2007, 94, 1009-1013. | 0.1 | 53 |
| 346 | The impact of screening and genetic registration on mortality and colorectal cancer incidence in familial adenomatous polyposis. Gut, 2010, 59, 1378-1382. | 6.1 | 53 |
| 347 | Constitutional rearrangements of chromosome 22 as a cause of neurofibromatosis 2. Journal of Medical Genetics, 2004, 41, 529-534. | 1.5 | 52 |
| 348 | Evidence for a colorectal cancer susceptibility locus on chromosome 3q21-q24 from a high-density SNP genome-wide linkage scan. Human Molecular Genetics, 2006, 15, 2903-2910. | 1.4 | 52 |
| 349 | Genetic testing and screening of individuals at risk of NF2. Clinical Genetics, 2012, 82, 416-424. | 1.0 | 52 |
| 350 | Vestibular schwannomas occur in schwannomatosis and should not be considered an exclusion criterion for clinical diagnosis. American Journal of Medical Genetics, Part A, 2012, 158A, 215-219. | 0.7 | 52 |
| 351 | Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls. Familial Cancer, 2017, 16, 433-440. | 0.9 | 52 |
| 352 | Randomised controlled trial of simvastatin treatment for autism in young children with neurofibromatosis type 1 (SANTA). Molecular Autism, 2018, 9, 12. | 2.6 | 52 |
| 353 | Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657. | 2.9 | 52 |
| 354 | Linkage and LOH studies in 19 cylindromatosis families show no evidence of genetic heterogeneity and refine the CYLD locus on chromosome 16q12-q13. Human Genetics, 2000, 106, 58-65. | 1.8 | 51 |
| 355 | Evaluation ofRAD50 in familial breast cancer predisposition. International Journal of Cancer, 2006, 118, 2911-2916. | 2.3 | 51 |
| 356 | Evidence of Linkage to Chromosome 9q22.33 in Colorectal Cancer Kindreds from the United Kingdom. Cancer Research, 2006, 66, 5003-5006. | 0.4 | 51 |
| 357 | Inherited predisposition to colorectal adenomas caused by multiple rare alleles of MUTYH but not OGG1, NUDT1, NTH1 or NEIL 1, 2 or 3. Gut, 2008, 57, 1252-1255. | 6.1 | 51 |
| 358 | Vestibular schwannoma: role of conservative management. Journal of Laryngology and Otology, 2010, 124, 251-257. | 0.4 | 51 |
| 359 | Pathology update to the Manchester Scoring System based on testing in over 4000 families. Journal of Medical Genetics, 2017, 54, 674-681. | 1.5 | 51 |
| 360 | A mutation in the neurofibromatosis type 2 tumor-suppressor gene, giving rise to widely different clinical phenotypes in two unrelated individuals. American Journal of Human Genetics, 1994, 55, 69-73. | 2.6 | 51 |

| # | Article | IF | Citations |
|---|---|---|---|
| 361 | Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. JAMA Oncology, 2022, 8, e216744. | 3.4 | 51 |
| 362 | Brain tumours and the occurrence of severe invasive basal cell carcinoma in first degree relatives with Gorlin syndrome. British Journal of Neurosurgery, 1991, 5, 643-646. | 0.4 | 50 |
| 363 | The spectrum of urological malignancy in Lynch syndrome. Familial Cancer, 2013, 12, 57-63. | 0.9 | 50 |
| 364 | Mutation screening of MSH2 and MLH1 mRNA in hereditary non-polyposis colon cancer syndrome.. Journal of Medical Genetics, 1996, 33, 726-730. | 1.5 | 49 |
| 365 | Genetic and functional studies of a germline TP53 splicing mutation in a Liâ€“Fraumeni-like family. Oncogene, 1998, 16, 3291-3298. | 2.6 | 49 |
| 366 | Patterns of associations of clinical features in neurofibromatosisÂ1 (NF1). Human Genetics, 2003, 112, 289-297. | 1.8 | 49 |
| 367 | BRCA1/2 predictive testing: a study of uptake in two centres. European Journal of Human Genetics, 2004, 12, 654-662. | 1.4 | 49 |
| 368 | Prevention and genetic testing for breast cancer: variations in medical decisions. Social Science and Medicine, 2004, 58, 1085-1096. | 1.8 | 49 |
| 369 | News on the genetics, epidemiology, medical care and translational research of Schwannomas. Journal of Neurology, 2006, 253, 1533-1541. | 1.8 | 49 |
| 370 | Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma?. Clinical Genetics, 2007, 71, 354-358. | 1.0 | 49 |
| 371 | Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Research, 2011, 71, 5792-5805. | 0.4 | 49 |
| 372 | Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-ÎºB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers. EBioMedicine, 2015, 2, 1331-1339. | 2.7 | 49 |
| 373 | ACTA OTORHINOLARYNGOLOGICA ITALICA. Acta Otorhinolaryngologica Italica, 2016, 36, 345-367. | 0.7 | 49 |
| 374 | Colorectal cancer incidence in path_MLH1 carriers subjected to different follow-up protocols: a Prospective Lynch Syndrome Database report. Hereditary Cancer in Clinical Practice, 2017, 15, 18. | 0.6 | 49 |
| 375 | The Fanconi Anemia Group E Gene, FANCE, Maps to Chromosome 6p. American Journal of Human Genetics, 1999, 64, 1400-1405. | 2.6 | 48 |
| 376 | SMARCB1 mutations are not a common cause of multiple meningiomas. Journal of Medical Genetics, 2010, 47, 567-568. | 1.5 | 48 |
| 377 | Fanconi anaemia,BRCA2mutations and childhood cancer: a developmental perspective from clinical and epidemiological observations with implications for genetic counselling. Journal of Medical Genetics, 2014, 51, 71-75. | 1.5 | 48 |
| 378 | Risk-based breast cancer screening strategies in women. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2020, 65, 3-17. | 1.4 | 48 |

| # | Article | IF | Citations |
|---|---|---|---|
| 379 | Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants. JAMA Oncology, 2020, 6, 1218. | 3.4 | 48 |
| 380 | A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. Lancet Oncology, The, 2021, 22, 1618-1631. | 5.1 | 48 |
| 381 | Evaluation of Fanconi Anemia genes in familial breast cancer predisposition. Cancer Research, 2003, 63, 8596-9. | 0.4 | 48 |
| 382 | Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 645-657. | 1.1 | 47 |
| 383 | DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256. | 1.5 | 47 |
| 384 | A heritable form of SMARCE1-related meningiomas with important implications for follow-up and family screening. Neurogenetics, 2016, 17, 83-89. | 0.7 | 47 |
| 385 | Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality. Hereditary Cancer in Clinical Practice, 2016, 14, 8. | 0.6 | 47 |
| 386 | Identifying the deficiencies of current diagnostic criteria for neurofibromatosis 2 using databases of 2777 individuals with molecular testing. Genetics in Medicine, 2019, 21, 1525-1533. | 1.1 | 47 |
| 387 | The heterogeneous nature of germline mutations in NF1 patients with malignant peripheral serve sheath tumours (MPNSTs). Human Mutation, 2006, 27, 716-716. | 1.1 | 46 |
| 388 | Comparison of proactive and usual approaches to offering predictive testing for BRCA1/2 mutations in unaffected relatives. Clinical Genetics, 2009, 75, 124-132. | 1.0 | 46 |
| 389 | Evaluation of a Stratified National Breast Screening Program in the United Kingdom: An Early Model-Based Cost-Effectiveness Analysis. Value in Health, 2017, 20, 1100-1109. | 0.1 | 46 |
| 390 | Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor Phenotypes. American Journal of Human Genetics, 2018, 103, 3-18. | 2.6 | 46 |
| 391 | Familial breast cancer: an investigation into the outcome of treatment for early stage disease. Familial Cancer, 2001, 1, 65-72. | 0.9 | 45 |
| 392 | Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis. Familial Cancer, 2015, 14, 531-538. | 0.9 | 45 |
| 393 | Body mass index and breast cancer survival: a Mendelian randomization analysis. International Journal of Epidemiology, 2017, 46, 1814-1822. | 0.9 | 45 |
| 394 | Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. Journal of the National Cancer Institute, 2021, 113, 329-337. | 3.0 | 45 |
| 395 | Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer. Frontiers in Immunology, 2019, 10, 3023. | 2.2 | 45 |
| 396 | Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations. European Journal of Human Genetics, 2013, 21, 212-216. | 1.4 | 44 |

| # | Article | IF | Citations |
|---|---|---|---|
| 397 | Disease expression in juvenile polyposis syndrome: a retrospective survey on a cohort of 221 European patients and comparison with a literature-derived cohort of 473 SMAD4/BMPR1A pathogenic variant carriers. Genetics in Medicine, 2020, 22, 1524-1532. | 1.1 | 44 |
| 398 | Use of a closed set questionnaire to measure primary and secondary effects of neurofibromatosis type 2. Journal of Laryngology and Otology, 2010, 124, 720-728. | 0.4 | 43 |
| 399 | Cognition in children with neurofibromatosis type 1: data from a populationâ€based study. Developmental Medicine and Child Neurology, 2015, 57, 645-651. | 1.1 | 43 |
| 400 | Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries. International Journal of Epidemiology, 2022, 50, 1897-1911. | 0.9 | 43 |
| 401 | Screening younger women with a family history of breast cancer â€“ does early detection improve outcome?. European Journal of Cancer, 2006, 42, 1385-1390. | 1.3 | 42 |
| 402 | Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status. British Journal of Cancer, 2010, 102, 1091-1098. | 2.9 | 42 |
| 403 | Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 2016, 18, 112. | 2.2 | 42 |
| 404 | Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report. Hereditary Cancer in Clinical Practice, 2019, 17, 8. | 0.6 | 42 |
| 405 | Abnormalities of the vitreoretinal interface caused by dysregulated Hedgehog signaling during retinal development. Human Molecular Genetics, 2003, 12, 3269-3276. | 1.4 | 41 |
| 406 | Surgical decisions made by 158 women with hereditary breast cancer aged <50 years. European Journal of Surgical Oncology, 2005, 31, 1112-1118. | 0.5 | 41 |
| 407 | Geneâ€“gene interactions in breast cancer susceptibility. Human Molecular Genetics, 2012, 21, 958-962. | 1.4 | 41 |
| 408 | Genotypeâ€“phenotype correlation in colorectal polyposis. Clinical Genetics, 2012, 81, 521-531. | 1.0 | 41 |
| 409 | Psychological impact of providing women with personalised 10-year breast cancer risk estimates. British Journal of Cancer, 2018, 118, 1648-1657. | 2.9 | 41 |
| 410 | Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2020, 22, 8. | 2.2 | 41 |
| 411 | APC mutations in familial adenomatous polyposis families in the Northwest of England. Human Mutation, 1997, 10, 376-380. | 1.1 | 40 |
| 412 | Neurofibromatosis Type 2. Advances in Oto-Rhino-Laryngology, 2011, 70, 91-98. | 1.6 | 40 |
| 413 | Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2011, 103, 105-116. | 3.0 | 40 |
| 414 | Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2. Journal of Medical Genetics, 2015, 52, 557-562. | 1.5 | 40 |

| # | Article | IF | Citations |
|---|---|---|---|
| 415 | Hearing optimisation in neurofibromatosis type 2: A systematic review. Clinical Otolaryngology, 2017, 42, 1329-1337. | 0.6 | 40 |
| 416 | Congenital anomalies and genetic syndromes in 173 cases of medulloblastoma. Medical and Pediatric Oncology, 1993, 21, 433-434. | 1.0 | 39 |
| 417 | Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2. Journal of Neurology, 2014, 261, 963-969. | 1.8 | 39 |
| 418 | Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation. Neuro-Oncology Practice, 2016, 3, 281-289. | 1.0 | 39 |
| 419 | Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort. Journal of Neuro-Oncology, 2017, 131, 117-124. | 1.4 | 39 |
| 420 | Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638. | 0.4 | 39 |
| 421 | Women's perceptions of personalized riskâ€based breast cancer screening and prevention: An international focus group study. Psycho-Oncology, 2019, 28, 1056-1062. | 1.0 | 39 |
| 422 | Hereditary Leiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and Screening Features in a Cohort of 185 Affected Individuals. European Urology Oncology, 2020, 3, 764-772. | 2.6 | 39 |
| 423 | Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. American Journal of Human Genetics, 2020, 107, 837-848. | 2.6 | 39 |
| 424 | Mutation Scanning of the NF2 Gene: An Improved Service Based on Meta-PCR/Sequencing, Dosage Analysis, and Loss of Heterozygosity Analysis. Genetic Testing and Molecular Biomarkers, 2004, 8, 368-380. | 1.7 | 38 |
| 425 | Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families. Clinical Genetics, 2008, 73, 338-345. | 1.0 | 38 |
| 426 | A caseâ€“control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density. International Journal of Cancer, 2020, 146, 2122-2129. | 2.3 | 38 |
| 427 | Cryopreservation of epididymal alpaca (Vicugna pacos) sperm: a comparison of citrate-, Tris- and lactose-based diluents and pellets and straws. Reproduction, Fertility and Development, 2007, 19, 792. | 0.1 | 37 |
| 428 | Association of the VariantsCASP8D302H andCASP10V410I with Breast and Ovarian Cancer Risk inBRCA1andBRCA2Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2859-2868. | 1.1 | 37 |
| 429 | Breast Cancer Risk in Young Women in the National Breast Screening Programme: Implications for Applying NICE Guidelines for Additional Screening and Chemoprevention. Cancer Prevention Research, 2014, 7, 993-1001. | 0.7 | 37 |
| 430 | Intermittent energy restriction induces changes in breast gene expression and systemic metabolism. Breast Cancer Research, 2016, 18, 57. | 2.2 | 37 |
| 431 | White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk. Annals of Internal Medicine, 2018, 168, 326. | 2.0 | 37 |
| 432 | The genetic interplay between body mass index, breast size and breast cancer risk: a Mendelian randomization analysis. International Journal of Epidemiology, 2019, 48, 781-794. | 0.9 | 37 |

| # | Article | IF | Citations |
|---|---|---|---|
| 433 | What are the benefits and harms of risk stratified screening as part of the NHS breast screening Programme? Study protocol for a multi-site non-randomised comparison of BC-predict versus usual screening (NCT04359420). BMC Cancer, 2020, 20, 570. | 1.1 | 37 |
| 434 | Microsatellite instability in early onset and familial colorectal cancer.. Journal of Medical Genetics, 1996, 33, 981-985. | 1.5 | 36 |
| 435 | Acute Chemotherapyâ€“Related Toxicity Is Not Increased in BRCA1 and BRCA2 Mutation Carriers Treated for Breast Cancer in the United Kingdom. Clinical Cancer Research, 2006, 12, 7033-7038. | 3.2 | 36 |
| 436 | Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients. Breast Cancer Research and Treatment, 2012, 133, 1191-1198. | 1.1 | 36 |
| 437 | Hearing and facial function outcomes for neurofibromatosis 2 clinical trials. Neurology, 2013, 81, S25-32. | 1.5 | 36 |
| 438 | Efficacy of Early Diagnosis and Treatment in Women with a Family History of Breast Cancer. Disease Markers, 1999, 15, 179-186. | 0.6 | 35 |
| 439 | A protocol for preventative mastectomy in women with an increased lifetime risk of breast cancer. European Journal of Surgical Oncology, 2000, 26, 711-713. | 0.5 | 35 |
| 440 | Breast cancer susceptibility variants alter risks in familial disease. Journal of Medical Genetics, 2010, 47, 126-131. | 1.5 | 35 |
| 441 | The inflammatory microenvironment in vestibular schwannoma. Neuro-Oncology Advances, 2020, 2, vdaa023. | 0.4 | 35 |
| 442 | Germline and sporadic cancers driven by the RAS pathway: parallelsÂandÂcontrasts. Annals of Oncology, 2020, 31, 873-883. | 0.6 | 35 |
| 443 | Do Women Understand the Odds? Risk Perceptions and Recall of Risk Information in Women with a Family History of Breast Cancer. Public Health Genomics, 2003, 6, 214-223. | 0.6 | 34 |
| 444 | Age related shift in the mutation spectra of germline and somatic NF2 mutations: hypothetical role of DNA repair mechanisms. Journal of Medical Genetics, 2005, 42, 630-632. | 1.5 | 34 |
| 445 | Accurate Prediction of BRCA1 and BRCA2 Heterozygous Genotype Using Expression Profiling after Induced DNA Damage. Clinical Cancer Research, 2006, 12, 3896-3901. | 3.2 | 34 |
| 446 | The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30â€“49. European Journal of Health Economics, 2007, 8, 137-144. | 1.4 | 34 |
| 447 | Prevalence of Adenomas and Hyperplastic Polyps in Mismatch Repair Mutation Carriers Among CAPP2 Participants: Report by the Colorectal Adenoma/Carcinoma Prevention Programme 2. Journal of Clinical Oncology, 2008, 26, 3434-3439. | 0.8 | 34 |
| 448 | Ovarian cancer susceptibility alleles and risk of ovarian cancer inBRCA1andBRCA2mutation carriers. Human Mutation, 2012, 33, 690-702. | 1.1 | 34 |
| 449 | A novel and fully automated mammographic texture analysis for risk prediction: results from two case-control studies. Breast Cancer Research, 2017, 19, 114. | 2.2 | 34 |
| 450 | Solving patients with rare diseases through programmatic reanalysis of genome-phenome data. European Journal of Human Genetics, 2021, 29, 1337-1347. | 1.4 | 34 |

| # | Article | IF | Citations |
|---|---|---|---|
| 451 | Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. American Journal of Obstetrics and Gynecology, 2021, 225, 51.e1-51.e17. | 0.7 | 34 |
| 452 | Advances in Neurofibromatosis 2 (NF2): A Workshop Report. Journal of Neurogenetics, 2000, 14, 63-106. | 0.6 | 33 |
| 453 | Methodological issues in longitudinal studies: vestibular schwannoma growth rates in neurofibromatosis 2. Journal of Medical Genetics, 2005, 42, 903-906. | 1.5 | 33 |
| 454 | Malignant peripheral nerve sheath tumours in NF1: Improved survival in women and in recent years. European Journal of Cancer, 2011, 47, 2723-2728. | 1.3 | 33 |
| 455 | Correspondence: Humanitarian Intervention and the Responsibility to Protect. International Security, 2013, 37, 199-214. | 1.4 | 33 |
| 456 | Clinical response to bevacizumab in schwannomatosis. Neurology, 2014, 83, 1986-1987. | 1.5 | 33 |
| 457 | Bilateral vestibular schwannomas in older patients: NF2 or chance?. Journal of Medical Genetics, 2015, 52, 422-424. | 1.5 | 33 |
| 458 | Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. JNCI Cancer Spectrum, 2018, 2, pky023. | 1.4 | 33 |
| 459 | What are the implications in individuals with unilateral vestibular schwannoma and other neurogenic tumors?. Journal of Neurosurgery, 2008, 108, 92-96. | 0.9 | 32 |
| 460 | Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Human Molecular Genetics, 2011, 20, 4732-4747. | 1.4 | 32 |
| 461 | Distribution of breast cancer risk from SNPs and classical risk factors in women of routine screening age in the UK. British Journal of Cancer, 2014, 110, 827-828. | 2.9 | 32 |
| 462 | Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women. American Journal of Obstetrics and Gynecology, 2018, 218, 431.e1-431.e12. | 0.7 | 32 |
| 463 | Deciphering the genetics of hereditary non-syndromic colorectal cancer. European Journal of Human Genetics, 2008, 16, 1477-1486. | 1.4 | 31 |
| 464 | Breast and Ovarian Cancer Risk and Risk Reduction in Jewish BRCA1/2 Mutation Carriers. Journal of Clinical Oncology, 2012, 30, 1321-1328. | 0.8 | 31 |
| 465 | Prevention of breast cancer in the context of a national breast screening programme. Journal of Internal Medicine, 2012, 271, 321-330. | 2.7 | 31 |
| 466 | The Manchester guidelines for contralateral risk-reducing mastectomy. World Journal of Surgical Oncology, 2015, 13, 237. | 0.8 | 31 |
| 467 | Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment. Breast Cancer Research and Treatment, 2017, 165, 433-444. | 1.1 | 31 |
| 468 | Increased risk of breast cancer in neurofibromatosis type 1: current insights. Breast Cancer: Targets and Therapy, 2017, Volume 9, 531-536. | 1.0 | 31 |

| # | Article | IF | Citations |
|---|---|---|---|
| 469 | Epithelial ovarian cancer risk: A review of the current genetic landscape. Clinical Genetics, 2020, 97, 54-63. | 1.0 | 31 |
| 470 | Assessment of relative risk of second primary tumors after ovarian cancer and of the usefulness of double primary cases as a source of material for genetic studies with a cancer registry. Cancer, 1993, 72, 819-827. | 2.0 | 30 |
| 471 | Use of MRI and audiological tests in presymptomatic diagnosis of type 2 neurofibromatosis (NF2). Journal of Medical Genetics, 2000, 37, 944-947. | 1.5 | 30 |
| 472 | Molecular stool screening for colorectal cancer. British Journal of Surgery, 2004, 91, 790-800. | 0.1 | 30 |
| 473 | Is CHEK2 a cause of the Li Fraumeni syndrome?. Journal of Medical Genetics, 2007, 45, 63-64. | 1.5 | 30 |
| 474 | An improved coverage and spatial resolutionâ€”using dual injection dynamic contrastâ€enhanced (ICEâ€ÐICE) MRI: A novel dynamic contrastâ€enhanced technique for cerebral tumors. Magnetic Resonance in Medicine, 2012, 68, 452-462. | 1.9 | 30 |
| 475 | Can the breast screening appointment be used to provide risk assessment and prevention advice?. Breast Cancer Research, 2015, 17, 84. | 2.2 | 30 |
| 476 | Pediatric intracranial clear cell meningioma associated with a germline mutation of SMARCE1: a novel case. Child's Nervous System, 2015, 31, 441-447. | 0.6 | 30 |
| 477 | Auditory Brainstem Implantation in Neurofibromatosis Type 2. Otology and Neurotology, 2016, 37, 1267-1274. | 0.7 | 30 |
| 478 | Are we ready for the challenge of implementing risk-based breast cancer screening and primary prevention?. Breast, 2018, 39, 24-32. | 0.9 | 30 |
| 479 | Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364. | 3.0 | 30 |
| 480 | Cancer Variant Interpretation Group UK (CanVIG-UK): an exemplar national subspecialty multidisciplinary network. Journal of Medical Genetics, 2020, 57, 829-834. | 1.5 | 30 |
| 481 | A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. Nature Communications, 2020, 11, 312. | 5.8 | 30 |
| 482 | Non-penetrance and late appearance of polyps in families with familial adenomatous polyposis.. Gut, 1993, 34, 1389-1393. | 6.1 | 29 |
| 483 | Utilisation of Prophylactic Mastectomy in 10 European Centres. Disease Markers, 1999, 15, 148-151. | 0.6 | 29 |
| 484 | New approaches to the endocrine prevention and treatment of breast cancer. Cancer Chemotherapy and Pharmacology, 2003, 52, 39-44. | 1.1 | 29 |
| 485 | Identification of genetic aberrations on chromosome 22 outside theNF2locus in schwannomatosis and neurofibromatosis type 2. Human Mutation, 2005, 26, 540-549. | 1.1 | 29 |
| 486 | Mechanisms of Disease: prediction and prevention of breast cancerâ€”cellular and molecular interactions. Nature Clinical Practice Oncology, 2005, 2, 635-646. | 4.3 | 29 |

| # | Article | IF | Citations |
|---|---|---|---|
| 487 | BRCA1/2 mutation analysis in male breast cancer families from North West England. Familial Cancer, 2008, 7, 113-117. | 0.9 | 29 |
| 488 | RIC-3 differentially modulates Î±4Î²2 and Î±7 nicotinic receptor assembly, expression, and nicotine-induced receptor upregulation. BMC Neuroscience, 2013, 14, 47. | 0.8 | 29 |
| 489 | Management of women at high risk of breast cancer. BMJ, The, 2014, 348, g2756-g2756. | 3.0 | 29 |
| 490 | Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens. Breast Cancer Research and Treatment, 2016, 155, 597-601. | 1.1 | 29 |
| 491 | WAGR syndrome and multiple exostoses in a patient with del(11)(p11.2p14.2). Journal of Medical Genetics, 1995, 32, 823-824. | 1.5 | 28 |
| 492 | Misleading linkage results in an NF2 presymptomatic test owing to mosaicism.. Journal of Medical Genetics, 1997, 34, 934-936. | 1.5 | 28 |
| 493 | Neurofibromatosis Type 2: Genetic and Clinical Features. Ear, Nose and Throat Journal, 1999, 78, 97-100. | 0.4 | 28 |
| 494 | Eight novelMSH6germline mutations in patients with familial and nonfamilial colorectal cancer selected by loss of protein expression in tumor tissue. Human Mutation, 2004, 23, 285-285. | 1.1 | 28 |
| 495 | Evidence for an Association between Compound Heterozygosity for Germ Line Mutations in the Hemochromatosis (HFE) Gene and Increased Risk of Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1460-1463. | 1.1 | 28 |
| 496 | A case of multiple cutaneous schwannomas; schwannomatosis or neurofibromatosis type 2?. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 269-271. | 0.9 | 28 |
| 497 | Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk. European Journal of Human Genetics, 2009, 17, 1381-1385. | 1.4 | 28 |
| 498 | Clinical presentation, immunohistochemistry and electron microscopy indicate neurofibromatosis type 2â€associated gliomas to be spinal ependymomas. Neuropathology, 2012, 32, 611-616. | 0.7 | 28 |
| 499 | Can the diagnosis of NF1 be excluded clinically? A lack of pigmentary findings in families with spinal neurofibromatosis demonstrates a limitation of clinical diagnosis. Journal of Medical Genetics, 2013, 50, 606-613. | 1.5 | 28 |
| 500 | The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38. | 2.3 | 28 |
| 501 | Association between genetic polymorphisms and endometrial cancer risk: a systematic review. Journal of Medical Genetics, 2020, 57, 591-600. | 1.5 | 28 |
| 502 | Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. Genetics in Medicine, 2021, 23, 705-712. | 1.1 | 28 |
| 503 | Implementation of Multigene Germline and Parallel Somatic Genetic Testing in Epithelial Ovarian Cancer: SIGNPOST Study. Cancers, 2021, 13, 4344. | 1.7 | 28 |
| 504 | Prediction of reader estimates of mammographic density using convolutional neural networks. Journal of Medical Imaging, 2019, 6, 1. | 0.8 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 505 | Diagnostic issues in a family with late onset type 2 neurofibromatosis.. Journal of Medical Genetics, 1995, 32, 470-474. | 1.5 | 27 |
| 506 | Is clinical growth index a reliable predictor of tumour growth in vestibular schwannomas?. Clinical Otolaryngology, 2003, 28, 85-90. | 0.0 | 27 |
| 507 | Semiquantitative assessment of immunohistochemistry for mismatch repair proteins in Lynch syndrome. Histopathology, 2010, 56, 331-344. | 1.6 | 27 |
| 508 | Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. British Journal of Cancer, 2012, 106, 2016-2024. | 2.9 | 27 |
| 509 | Outcome of translabyrinthine surgery for vestibular schwannoma in neurofibromatosis type 2. British Journal of Neurosurgery, 2013, 27, 446-453. | 0.4 | 27 |
| 510 | Increased rate of missense/in-frame mutations in individuals with NF1-related pulmonary stenosis: a novel genotypeâ€“phenotype correlation. European Journal of Human Genetics, 2013, 21, 535-539. | 1.4 | 27 |
| 511 | Intronic splicing mutations in PTCH1 cause Gorlin syndrome. Familial Cancer, 2014, 13, 477-480. | 0.9 | 27 |
| 512 | Vascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis. Neuro-Oncology, 2016, 18, 275-282. | 0.6 | 27 |
| 513 | Women's decision-making regarding risk-stratified breast cancer screening and prevention from the perspective of international healthcare professionals. PLoS ONE, 2018, 13, e0197772. | 1.1 | 27 |
| 514 | Survival by colon cancer stage and screening interval in Lynch syndrome: a prospective Lynch syndrome database report. Hereditary Cancer in Clinical Practice, 2019, 17, 28. | 0.6 | 27 |
| 515 | Risk stratified breast cancer screening: UK healthcare policy decision-making stakeholdersâ€™ views on a low-risk breast screening pathway. BMC Cancer, 2020, 20, 680. | 1.1 | 27 |
| 516 | NF1 optic pathway glioma: analyzing risk factors for visual outcome and indications to treat. Neuro-Oncology, 2021, 23, 100-111. | 0.6 | 27 |
| 517 | Genetic linkage analysis in hereditary non-polyposis colon cancer syndrome.. Journal of Medical Genetics, 1995, 32, 352-357. | 1.5 | 26 |
| 518 | BRCA1 and BRCA2 Cancer Risks. Journal of Clinical Oncology, 2006, 24, 3312-3313. | 0.8 | 26 |
| 519 | English Consensus Protocol Evaluating Candidacy for Auditory Brainstem and Cochlear Implantation in Neurofibromatosis Type 2. Otology and Neurotology, 2013, 34, 1743-1747. | 0.7 | 26 |
| 520 | Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men. Scientific Reports, 2013, 3, 2059. | 1.6 | 26 |
| 521 | An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61. | 2.2 | 26 |
| 522 | Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Research, 2015, 17, 58. | 2.2 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 523 | SMARCE1 mutations in pediatric clear cell meningioma: case report. Journal of Neurosurgery: Pediatrics, 2015, 16, 296-300. | 0.8 | 26 |
| 524 | Outcomes of cochlear implantation in patients with neurofibromatosis type 2. Cochlear Implants International, 2016, 17, 172-177. | 0.5 | 26 |
| 525 | Sensitivity of BRCA1/2 testing in high-risk breast/ovarian/male breast cancer families: little contribution of comprehensive RNA/NGS panel testing. European Journal of Human Genetics, 2016, 24, 1591-1597. | 1.4 | 26 |
| 526 | Breast cancer risk in neurofibromatosis type 1 is a function of the type of NF1 gene mutation: a new genotype-phenotype correlation. Journal of Medical Genetics, 2019, 56, 209-219. | 1.5 | 26 |
| 527 | Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study. Genetics in Medicine, 2020, 22, 398-406. | 1.1 | 26 |
| 528 | BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study. European Journal of Cancer, 2020, 136, 169-175. | 1.3 | 26 |
| 529 | A system for enabling blind people to identify landmarks: the sound buoy. IEEE Transactions on Rehabilitation Engineering: A Publication of the IEEE Engineering in Medicine and Biology Society, 1997, 5, 276-278. | 1.4 | 25 |
| 530 | Exploring the â€œtwo-hit hypothesisâ€•in NF2: Tests of two-hit and three-hit models of vestibular schwannoma development. Genetic Epidemiology, 2003, 24, 265-272. | 0.6 | 25 |
| 531 | Sensitization to wheat flour and enzymes and associated respiratory symptoms in British bakers. American Journal of Industrial Medicine, 2009, 52, 133-140. | 1.0 | 25 |
| 532 | Childhood predictive genetic testing for Liâ€“Fraumeni syndrome. Familial Cancer, 2010, 9, 65-69. | 0.9 | 25 |
| 533 | ORIGINAL ARTICLE: The relationship between patientsâ€™ perception of the effects of neurofibromatosis type 2 and the domains of the Short Formâ€36. Clinical Otolaryngology, 2010, 35, 291-299. | 0.6 | 25 |
| 534 | Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2mutation carriers. Breast Cancer Research, 2010, 12, R102. | 2.2 | 25 |
| 535 | Beliefs about weight and breast cancer: an interview study with high risk women following a 12Âmonth weight loss intervention. Hereditary Cancer in Clinical Practice, 2015, 13, 1. | 0.6 | 25 |
| 536 | Homozygous germ-line mutation of the PMS2 mismatch repair gene: a unique case report of constitutional mismatch repair deficiency (CMMRD). BMC Medical Genetics, 2017, 18, 40. | 2.1 | 25 |
| 537 | The response of spinal cord ependymomas to bevacizumab in patients with neurofibromatosis Type 2. Journal of Neurosurgery: Spine, 2017, 26, 474-482. | 0.9 | 25 |
| 538 | Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancerâ€”an European consensus statement and expert recommendations. European Journal of Cancer, 2019, 106, 54-60. | 1.3 | 25 |
| 539 | Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal (PROTECTOR): protocol for a prospective non-randomised multi-center trial. International Journal of Gynecological Cancer, 2021, 31, 286-291. | 1.2 | 25 |
| 540 | Family implications of neonatal Gorlin's syndrome.. Archives of Disease in Childhood, 1991, 66, 1162-1163. | 1.0 | 24 |

| # | Article | IF | Citations |
|---|---|---|---|
| 541 | Rationale for a national multi-centre study of magnetic resonance imaging screening in women at genetic risk of breast cancer. Breast, 2000, 9, 72-77. | 0.9 | 24 |
| 542 | Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations. British Journal of Cancer, 2006, 94, 1021-1028. | 2.9 | 24 |
| 543 | International variation in physiciansâ€™ attitudes towards prophylactic mastectomy â€“ Comparison between France, Germany, the Netherlands and the United Kingdom. European Journal of Cancer, 2013, 49, 2798-2805. | 1.3 | 24 |
| 544 | Mutation type and position varies between mosaic and inherited <scp>NF2</scp> and correlates with disease severity. Clinical Genetics, 2013, 83, 594-595. | 1.0 | 24 |
| 545 | Spinal ependymomas in NF2: a surgical disease?. Journal of Neuro-Oncology, 2018, 136, 605-611. | 1.4 | 24 |
| 546 | Malignant Peripheral Nerve Sheath Tumors are not a Feature of Neurofibromatosis Type 2 in the Unirradiated Patient. Neurosurgery, 2018, 83, 38-42. | 0.6 | 24 |
| 547 | Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 368-378. | 1.1 | 24 |
| 548 | The importance of ethnicity: Are breast cancer polygenic risk scores ready for women who are not of White European origin?. International Journal of Cancer, 2022, 150, 73-79. | 2.3 | 24 |
| 549 | Variation of expression of the gene for type 2 neurofibromatosis: absence of a gender effect on vestibular schwannomas, but confirmation of a preponderance of meningiomas in females. Journal of Laryngology and Otology, 1995, 109, 830-835. | 0.4 | 23 |
| 550 | Suggested Screening Guidelines for Familial Colorectal Cancer. Journal of Medical Screening, 1995, 2, 45-51. | 1.1 | 23 |
| 551 | False family history of breast cancer in the family cancer clinic. European Journal of Surgical Oncology, 1998, 24, 275-279. | 0.5 | 23 |
| 552 | Differential diagnosis of type 2 neurofibromatosis: molecular discrimination of NF2 and sporadic vestibular schwannomas.. Journal of Medical Genetics, 1998, 35, 973-977. | 1.5 | 23 |
| 553 | Ethical, Social and Economic Issues in Familial Breast Cancer: A Compilation of Views from the E.C. Biomed II Demonstration Project. Disease Markers, 1999, 15, 125-131. | 0.6 | 23 |
| 554 | Intrafamilial correlation of clinical manifestations in neurofibromatosis 2 (NF2). Genetic Epidemiology, 2002, 23, 245-259. | 0.6 | 23 |
| 555 | Exploring the link between MORF4L1 and risk of breast cancer. Breast Cancer Research, 2011, 13, R40. | 2.2 | 23 |
| 556 | A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1362-1370. | 1.1 | 23 |
| 557 | Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: Further evidence of benefit. International Journal of Cancer, 2012, 131, 417-425. | 2.3 | 23 |
| 558 | Ovarian cancer among 8005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative forBRCA1andBRCA2. Journal of Medical Genetics, 2013, 50, 368-372. | 1.5 | 23 |

| # | Article | IF | Citations |
|---|---|---|---|
| 559 | Current status and recommendations for biomarkers and biobanking in neurofibromatosis. Neurology, 2016, 87, S40-8. | 1.5 | 23 |
| 560 | Diagnosis of sporadic neurofibromatosis type 2 in the paediatric population. Archives of Disease in Childhood, 2018, 103, 463-469. | 1.0 | 23 |
| 561 | UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants. Journal of Medical Genetics, 2021, 58, 135-139. | 1.5 | 23 |
| 562 | The microenvironment in sporadic and neurofibromatosis type IIâ€“related vestibular schwannoma: the same tumor or different? A comparative imaging and neuropathology study. Journal of Neurosurgery, 2021, 134, 1419-1429. | 0.9 | 23 |
| 563 | The introduction of risk stratified screening into the NHS breast screening Programme: views from British-Pakistani women. BMC Cancer, 2020, 20, 452. | 1.1 | 23 |
| 564 | Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362. | 1.4 | 23 |
| 565 | Breast cancer risk stratification in women of screening age: Incremental effects of adding mammographic density, polygenic risk, and a gene panel. Genetics in Medicine, 2022, 24, 1485-1494. | 1.1 | 23 |
| 566 | Eleven novel mutations in the NF2 tumour suppressor gene. Human Genetics, 1995, 95, 572-4. | 1.8 | 22 |
| 567 | Cancer genetics clinics. European Journal of Cancer, 1996, 32, 391-392. | 1.3 | 22 |
| 568 | Protocol for a national multi-centre study of magnetic resonance imaging screening in women at genetic risk of breast cancer. Breast, 2000, 9, 78-82. | 0.9 | 22 |
| 569 | Effect of Seminal Plasma Fractions From Entire and Vasectomized Rams on the Motility Characteristics, Membrane Status, and In Vitro Fertility of Ram Spermatozoa. Journal of Andrology, 2006, 28, 109-122. | 2.0 | 22 |
| 570 | Radiation-induced brain tumours in nevoid basal cell carcinoma syndrome: implications for treatment and surveillance. Child's Nervous System, 2006, 23, 133-136. | 0.6 | 22 |
| 571 | Cutaneous lymphangioma and amegakaryocytic thrombocytopenia in Noonan syndrome. Clinical Genetics, 1991, 39, 228-232. | 1.0 | 22 |
| 572 | An update on age related mosaic and offspring risk in neurofibromatosis 2 (NF2). Journal of Medical Genetics, 2009, 46, 792-792. | 1.5 | 22 |
| 573 | Outcome from surgery for vestibular schwannomas in children. British Journal of Neurosurgery, 2009, 23, 226-231. | 0.4 | 22 |
| 574 | Hormone Replacement Therapy and Breast Cancer. Recent Results in Cancer Research, 2010, 188, 115-124. | 1.8 | 22 |
| 575 | Psychological impact and acceptability of magnetic resonance imaging and X-ray mammography: the MARIBS Study. British Journal of Cancer, 2011, 104, 578-586. | 2.9 | 22 |
| 576 | Uptake of risk-reducing salpingo-oophorectomy in women carrying a BRCA1 or BRCA2 mutation: evidence for lower uptake in women affected by breast cancer and older women. British Journal of Cancer, 2012, 106, 775-779. | 2.9 | 22 |

| # | Article | IF | Citations |
|---|---|---|---|
| 577 | Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers. Breast Cancer Research, 2012, 14, R63. | 2.2 | 22 |
| 578 | Breast cancer risk assessment in 8,824 women attending a family history evaluation and screening programme. Familial Cancer, 2014, 13, 189-196. | 0.9 | 22 |
| 579 | A pooled analysis of the outcome of prospective colonoscopic surveillance for familial colorectal cancer. International Journal of Cancer, 2014, 134, 939-947. | 2.3 | 22 |
| 580 | Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316. | 1.1 | 22 |
| 581 | Cost-effectiveness analysis of reflex testing for Lynch syndrome in women with endometrial cancer in the UK setting. PLoS ONE, 2019, 14, e0221419. | 1.1 | 22 |
| 582 | Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England. European Journal of Human Genetics, 2020, 28, 1541-1547. | 1.4 | 22 |
| 583 | Current recommendations for cancer surveillance in Gorlin syndrome: a report from the SIOPE host genome working group (SIOPE HGWG). Familial Cancer, 2021, 20, 317-325. | 0.9 | 22 |
| 584 | Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649). Oncotarget, 2014, 5, 8223-8234. | 0.8 | 22 |
| 585 | Fatal congenital cytomegalovirus infection acquired by an intra-uterine transfusion. European Journal of Pediatrics, 1991, 150, 780-781. | 1.3 | 21 |
| 586 | BRCA2: a cause of Li Fraumeni-like syndrome. Journal of Medical Genetics, 2007, 45, 62-63. | 1.5 | 21 |
| 587 | Strategies for Identifying Hereditary Nonpolyposis Colon Cancer. Seminars in Oncology, 2007, 34, 411-417. | 0.8 | 21 |
| 588 | Fine-Mapping CASP8 Risk Variants in Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 176-181. | 1.1 | 21 |
| 589 | A clinical and genetic analysis of multiple primary cancer referrals to genetics services. European Journal of Human Genetics, 2015, 23, 581-587. | 1.4 | 21 |
| 590 | A Method to Exploit the Structure of Genetic Ancestry Space to Enhance Case-Control Studies. American Journal of Human Genetics, 2016, 98, 857-868. | 2.6 | 21 |
| 591 | Genetic testing in a cohort of young patients with HER2-amplified breast cancer. Annals of Oncology, 2016, 27, 467-473. | 0.6 | 21 |
| 592 | Systematic review of the empirical investigation of resources to support decision-making regarding BRCA1 and BRCA2 genetic testing in women with breast cancer. Patient Education and Counseling, 2018, 101, 779-788. | 1.0 | 21 |
| 593 | The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations. JNCI Cancer Spectrum, 2018, 2, pky078. | 1.4 | 21 |
| 594 | Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases. Journal of Medical Genetics, 2019, 56, 301-307. | 1.5 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 595 | Predictors of weight gain in a cohort of premenopausal early breast cancer patients receiving chemotherapy. Breast, 2019, 45, 1-6. | 0.9 | 21 |
| 596 | Breast cancer risk status influences uptake, retention and efficacy of a weight loss programme amongst breast cancer screening attendees: two randomised controlled feasibility trials. BMC Cancer, 2019, 19, 1089. | 1.1 | 21 |
| 597 | Engagement barriers and service inequities in the NHS Breast Screening Programme: Views from British-Pakistani women. Journal of Medical Screening, 2020, 27, 130-137. | 1.1 | 21 |
| 598 | Young adulthood body mass index, adult weight gain and breast cancer risk: the PROCAS Study (United) Tj ETQq0 0 0 rgBT /Overlock 10 | 2.9 | 21 |
| 599 | Risk of Contralateral Breast Cancer in Women with and without Pathogenic Variants in BRCA1, BRCA2, and TP53 Genes in Women with Very Early-Onset (<36 Years) Breast Cancer. Cancers, 2020, 12, 378. | 1.7 | 21 |
| 600 | Fictitious breast cancer family history. Lancet, The, 1996, 348, 1034. | 6.3 | 20 |
| 601 | Physical localisation of the breakpoints of a constitutional translocation t(5;6)(q21;q21) in a child with bilateral Wilms' tumour.. Journal of Medical Genetics, 1997, 34, 343-345. | 1.5 | 20 |
| 602 | Neurofibromatosis 2 (NF2) and Malignant Mesothelioma in a Man with a Constitutional NF2 Missense Mutation. Familial Cancer, 2005, 4, 321-322. | 0.9 | 20 |
| 603 | Predicting Compliance in a Breast Cancer Prevention Trial. Breast Journal, 2006, 12, 446-450. | 0.4 | 20 |
| 604 | Inherited association of breast and colorectal cancer: limited role of CHEK2 compared with high-penetrance genes. Clinical Genetics, 2006, 70, 388-395. | 1.0 | 20 |
| 605 | Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk. International Journal of Cancer, 2013, 133, 156-163. | 2.3 | 20 |
| 606 | Rail grinding for the 21st century â€“ taking a lead from the aerospace industry. Proceedings of the Institution of Mechanical Engineers, Part F: Journal of Rail and Rapid Transit, 2015, 229, 457-465. | 1.3 | 20 |
| 607 | Urgent improvements needed to diagnose and manage Lynch syndrome. BMJ: British Medical Journal, 2017, 356, j1388. | 2.4 | 20 |
| 608 | Neurofibromatosis type 2 and related disorders. Current Opinion in Oncology, 2019, 31, 562-567. | 1.1 | 20 |
| 609 | Disease course of neurofibromatosis type 2: a 30-year follow-up study of 353 patients seen at a single institution. Neuro-Oncology, 2021, 23, 1113-1124. | 0.6 | 20 |
| 610 | Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis. British Journal of Cancer, 2020, 123, 268-274. | 2.9 | 20 |
| 611 | Current recommendations for clinical surveillance and genetic testing in rhabdoid tumor predisposition: a report from the SIOPE Host Genome Working Group. Familial Cancer, 2021, 20, 305-316. | 0.9 | 20 |
| 612 | The Angelina Jolie effect: Contralateral risk-reducing mastectomy trends in patients at increased risk of breast cancer. Scientific Reports, 2021, 11, 2847. | 1.6 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 613 | Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?. Breast Cancer Research, 2003, 6, E7. | 2.2 | 19 |
| 614 | High-resolution array-CGH profiling of germline and tumor-specific copy number alterations on chromosome 22 in patients affected with schwannomas. Human Genetics, 2005, 118, 35-44. | 1.8 | 19 |
| 615 | The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2009, 101, 1456-1460. | 2.9 | 19 |
| 616 | RASSF1A polymorphism in familial breast cancer. Familial Cancer, 2010, 9, 263-265. | 0.9 | 19 |
| 617 | Lynch syndrome screening in gynaecological cancers: results of an international survey with recommendations for uniform reporting terminology for mismatch repair immunohistochemistry results. Histopathology, 2019, 75, 813-824. | 1.6 | 19 |
| 618 | Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192. | 2.9 | 19 |
| 619 | Beliefs About Medication and Uptake of Preventive Therapy in Women at Increased Risk of Breast Cancer: Results From a Multicenter Prospective Study. Clinical Breast Cancer, 2019, 19, e116-e126. | 1.1 | 19 |
| 620 | Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years. Breast Cancer Research, 2020, 22, 101. | 2.2 | 19 |
| 621 | European womenâ€™s perceptions of the implementation and organisation of risk-based breast cancer screening and prevention: a qualitative study. BMC Cancer, 2020, 20, 247. | 1.1 | 19 |
| 622 | A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078. | 5.8 | 19 |
| 623 | Cognitive and Electrophysiological Correlates of Working Memory Impairments in Neurofibromatosis Type 1. Journal of Autism and Developmental Disorders, 2022, 52, 1478-1494. | 1.7 | 19 |
| 624 | Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use. Neurology, 2021, 97, S91-S98. | 1.5 | 19 |
| 625 | Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122. | 3.0 | 19 |
| 626 | Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 623-642. | 1.1 | 19 |
| 627 | Breast cancer risks associated with missense variants in breast cancer susceptibility genes. Genome Medicine, 2022, 14, 51. | 3.6 | 19 |
| 628 | Ovarian cancer family and prophylactic choices.. Journal of Medical Genetics, 1992, 29, 416-418. | 1.5 | 18 |
| 629 | Cost analysis of biomarker testing for mismatch repair deficiency in node-positive colorectal cancer. British Journal of Surgery, 2008, 95, 868-875. | 0.1 | 18 |
| 630 | Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Human Genetics, 2011, 130, 685-699. | 1.8 | 18 |

| # | Article | IF | Citations |
|---|---|---|---|
| 631 | Improving the uptake of predictive testing and colorectal screening in Lynch syndrome: a regional primary care survey. Clinical Genetics, 2015, 87, 517-524. | 1.0 | 18 |
| 632 | Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134. | 1.1 | 18 |
| 633 | Personalized prevention in high risk individuals: Managing hormones and beyond. Breast, 2018, 39, 139-147. | 0.9 | 18 |
| 634 | Breast cancer risk in a screening cohort of Asian and white British/Irish women from Manchester UK. BMC Public Health, 2018, 18, 178. | 1.2 | 18 |
| 635 | Trends in phenotype in the English paediatric neurofibromatosis type 2 cohort stratified by genetic severity. Clinical Genetics, 2019, 96, 151-162. | 1.0 | 18 |
| 636 | Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study). Journal of Pathology: Clinical Research, 2019, 5, 189-198. | 1.3 | 18 |
| 637 | Global Disparities in Breast Cancer Genetics Testing, Counselling and Management. World Journal of Surgery, 2019, 43, 1264-1270. | 0.8 | 18 |
| 638 | Lynch syndrome for the gynaecologist. The Obstetrician and Gynaecologist, 2021, 23, 9-20. | 0.2 | 18 |
| 639 | Haplotype and cancer risk analysis of two common mutations, BRCA1 4184del4 and BRCA2 2157delG, in high risk northwest England breast/ovarian families. Journal of Medical Genetics, 2004, 41, 21e-21. | 1.5 | 17 |
| 640 | Delivering cancer genetics services-new ways of working. Familial Cancer, 2007, 6, 163-167. | 0.9 | 17 |
| 641 | Update from the 2013 international neurofibromatosis conference. American Journal of Medical Genetics, Part A, 2014, 164, 2969-2978. | 0.7 | 17 |
| 642 | False-negative MRI breast screening in high-risk women. Clinical Radiology, 2017, 72, 207-216. | 0.5 | 17 |
| 643 | Psychosocial issues of a population approach to high genetic risk identification: Behavioural, emotional and informed choice issues. Breast, 2018, 37, 148-153. | 0.9 | 17 |
| 644 | Boosting care and knowledge about hereditary cancer: European Reference Network on Genetic Tumour Risk Syndromes. Familial Cancer, 2019, 18, 281-284. | 0.9 | 17 |
| 645 | 30 year experience of index case identification and outcomes of cascade testing in high-risk breast and colorectal cancer predisposition genes. European Journal of Human Genetics, 2022, 30, 413-419. | 1.4 | 17 |
| 646 | A clinical, genetic and audiological study of patients and families with unilateral vestibular schwannomas. I. Clinical features of neurofibromatosis in patients with unilateral vestibular schwannomas. Journal of Laryngology and Otology, 1996, 110, 634-640. | 0.4 | 16 |
| 647 | Molecular genetic tests in surgical management of familial adenomatous polyposis. Lancet, The, 1997, 350, 1777. | 6.3 | 16 |
| 648 | A novel TP53 splicing mutation in a Li-Fraumeni syndrome family: a patient with Wilms' tumour is not a mutation carrier. British Journal of Cancer, 1998, 78, 1081-1083. | 2.9 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 649 | Pathogenesis of vestibular schwannoma in ring chromosome 22. BMC Medical Genetics, 2009, 10, 97. | 2.1 | 16 |
| 650 | Uptake of breast cancer prevention and screening trials. Journal of Medical Genetics, 2010, 47, 853-855. | 1.5 | 16 |
| 651 | Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1032-1038. | 1.1 | 16 |
| 652 | Reduced life expectancy seen in hereditary diseases which predispose to early-onset tumors. The Application of Clinical Genetics, 2013, 6, 53. | 1.4 | 16 |
| 653 | Cancer risk communication, predictive testing and management in France, Germany, the Netherlands and the UK: general practitioners' and breast surgeons' current practice and preferred practice responsibilities. Journal of Community Genetics, 2014, 5, 69-79. | 0.5 | 16 |
| 654 | Neurofibromatosis type 2 service delivery in England. Neurochirurgie, 2018, 64, 375-380. | 0.6 | 16 |
| 655 | The association between weight at birth and breast cancer risk revisited using Mendelian randomisation. European Journal of Epidemiology, 2019, 34, 591-600. | 2.5 | 16 |
| 656 | Germline TP53 Testing in Breast Cancers: Why, When and How?. Cancers, 2020, 12, 3762. | 1.7 | 16 |
| 657 | Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelines. Human Mutation, 2020, 41, 1555-1562. | 1.1 | 16 |
| 658 | The predictive ability of the 313 variantâ€“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737. | 1.1 | 16 |
| 659 | A survey of the current clinical facilities for the management of familial cancer in Europe. Journal of Medical Genetics, 2000, 37, 605-607. | 1.5 | 15 |
| 660 | Stereotactic radiosurgery XI. Acoustic neuroma therapy and radiation oncogenesis. British Journal of Neurosurgery, 2000, 14, 93-95. | 0.4 | 15 |
| 661 | Genotype-phenotype correlations for cataracts in neurofibromatosis 2. Journal of Medical Genetics, 2003, 40, 758-760. | 1.5 | 15 |
| 662 | Better Life Expectancy in Women with BRCA2 Compared with BRCA1 Mutations Is Attributable to Lower Frequency and Later Onset of Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1535-1542. | 1.1 | 15 |
| 663 | Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). British Journal of Cancer, 2009, 101, 2048-2054. | 2.9 | 15 |
| 664 | A comparative study of quantitative immunohistochemistry and quantum dot immunohistochemistry for mutation carrier identification in Lynch syndrome. Journal of Clinical Pathology, 2011, 64, 208-214. | 1.0 | 15 |
| 665 | Long-term prospective clinical follow-up afterBRCA1/2presymptomatic testing:BRCA2risks higher than in adjusted retrospective studies. Journal of Medical Genetics, 2014, 51, 573-580. | 1.5 | 15 |
| 666 | Contralateral Risk-Reducing Mastectomy: Review of Risk Factors and Risk-Reducing Strategies. International Journal of Surgical Oncology, 2015, 2015, 1-7. | 0.3 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 667 | Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study. Genetics in Medicine, 2018, 20, 1575-1582. | 1.1 | 15 |
| 668 | The prevalence of Lynch syndrome in women with endometrial cancer: a systematic review protocol. Systematic Reviews, 2018, 7, 121. | 2.5 | 15 |
| 669 | Confirmation that somatic mutations of betaâ€2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trial. Histopathology, 2019, 75, 236-246. | 1.6 | 15 |
| 670 | European Breast Cancer Council manifesto 2018: GeneticÂrisk prediction testing in breast cancer. European Journal of Cancer, 2019, 106, 45-53. | 1.3 | 15 |
| 671 | Familial unilateral vestibular schwannoma is rarely caused by inherited variants in the NF2 gene. Laryngoscope, 2019, 129, 967-973. | 1.1 | 15 |
| 672 | Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic TP53 mutation carriers: a case-controlled study (SIGNIFY). Journal of Medical Genetics, 2020, 57, 226-236. | 1.5 | 15 |
| 673 | Targeting lung cancer screening to individuals at greatest risk: the role of genetic factors. Journal of Medical Genetics, 2021, 58, 217-226. | 1.5 | 15 |
| 674 | Extending screening intervals for women at low risk of breast cancer: do they find it acceptable?. BMC Cancer, 2021, 21, 637. | 1.1 | 15 |
| 675 | Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer?. Journal of Clinical Oncology, 2011, 29, 1501-1501. | 0.8 | 15 |
| 676 | Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research, 2022, 24, 2. | 2.2 | 15 |
| 677 | Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci. Breast Cancer Research, 2022, 24, 27. | 2.2 | 15 |
| 678 | Cancer Genetics Services in Europe. Disease Markers, 1999, 15, 3-13. | 0.6 | 14 |
| 679 | Can hair be used to screen for breast cancer?. Journal of Medical Genetics, 2000, 37, 297-298. | 1.5 | 14 |
| 680 | Dento-osseous changes as diagnostic markers in familial adenomatous polyposis families. Oral Diseases, 2003, 9, 29-33. | 1.5 | 14 |
| 681 | Dominantly inherited microcephaly, hypotelorism and normal intelligence. Clinical Genetics, 1991, 39, 178-180. | 1.0 | 14 |
| 682 | Eligibility for Magnetic Resonance Imaging Screening in the United Kingdom: Effect of Strict Selection Criteria and Anonymous DNA Testing on Breast Cancer Incidence in the MARIBS Study. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2123-2131. | 1.1 | 14 |
| 683 | Risk reducing salpingectomy and delayed oophorectomy in high risk women: views of cancer geneticists, genetic counsellors and gynaecological oncologists in the UK. Familial Cancer, 2015, 14, 521-530. | 0.9 | 14 |
| 684 | Progress of hearing loss in neurofibromatosis type 2: implications for future management. European Archives of Oto-Rhino-Laryngology, 2015, 272, 3143-3150. | 0.8 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 685 | Re-evaluating genetic variants identified in candidate gene studies of breast cancer risk using data from nearly 280,000 women of Asian and European ancestry. EBioMedicine, 2019, 48, 203-211. | 2.7 | 14 |
| 686 | Distinct Reproductive Risk Profiles for Intrinsic-Like Breast Cancer Subtypes: Pooled Analysis of Population-Based Studies. Journal of the National Cancer Institute, 2022, 114, 1706-1719. | 3.0 | 14 |
| 687 | Insurance Implications for Individuals with a High Risk of Breast and Ovarian Cancer in Europe. Disease Markers, 1999, 15, 159-165. | 0.6 | 13 |
| 688 | A follow-up study of breast and other cancers in families of an unselected series of breast cancer patients. British Journal of Cancer, 2002, 86, 718-722. | 2.9 | 13 |
| 689 | Sensitivity of BRCA1/2 mutation testing in 466 breast/ovarian cancer families. Journal of Medical Genetics, 2003, 40, 107e-107. | 1.5 | 13 |
| 690 | Sensitive Detection of Deletions of One or More Exons in the Neurofibromatosis Type 2 (NF2) Gene by Multiplexed Gene Dosage Polymerase Chain Reaction. Journal of Molecular Diagnostics, 2005, 7, 97-104. | 1.2 | 13 |
| 691 | Adult weight gain and central obesity in women with and without a family history of breast cancer: a case control study. Familial Cancer, 2007, 6, 287-294. | 0.9 | 13 |
| 692 | The <scp>MSH2</scp> c.388_389del mutation shows a founder effect in Portuguese Lynch syndrome families. Clinical Genetics, 2013, 84, 244-250. | 1.0 | 13 |
| 693 | Increased Rate of Phenocopies in All Age Groups in BRCA1/BRCA2 Mutation Kindred, but Increased Prospective Breast Cancer Risk Is Confined to BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 2269-2276. | 1.1 | 13 |
| 694 | Lymphocyte Telomere Length Is Long in BRCA1 and BRCA2 Mutation Carriers Regardless of Cancer-Affected Status. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1018-1024. | 1.1 | 13 |
| 695 | Mammographic surveillance in women aged 35â€“39 at enhanced familial risk of breast cancer (FH02). Familial Cancer, 2014, 13, 13-21. | 0.9 | 13 |
| 696 | In Silico Analysis of NF2 Gene Missense Mutations in Neurofibromatosis Type 2. Otology and Neurotology, 2015, 36, 908-914. | 0.7 | 13 |
| 697 | Creation of an international registry to support discovery in schwannomatosis. American Journal of Medical Genetics, Part A, 2017, 173, 407-413. | 0.7 | 13 |
| 698 | Results of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing. Scientific Reports, 2019, 9, 18555. | 1.6 | 13 |
| 699 | Assessment of mismatch repair deficiency in ovarian cancer. Journal of Medical Genetics, 2021, 58, 687-691. | 1.5 | 13 |
| 700 | Specialist oncological surgery for removal of the ovaries and fallopian tubes in <scp>BRCA1</scp> and <scp>BRCA2</scp> pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels. International Journal of Cancer, 2021, 148, 1155-1163. | 2.3 | 13 |
| 701 | A mismatch in care: results of a United Kingdomâ€wide patient and clinician survey of gynaecological services for women with Lynch syndrome. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, 128, 728-736. | 1.1 | 13 |
| 702 | The spatial phenotype of genotypically distinct meningiomas demonstrate potential implications of the embryology of the meninges. Oncogene, 2021, 40, 875-884. | 2.6 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 703 | Attitudes towards riskâ€reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, 128, 714-726. | 1.1 | 13 |
| 704 | High likelihood of actionable pathogenic variant detection in breast cancer genes in women with very early onset breast cancer. Journal of Medical Genetics, 2022, 59, 115-121. | 1.5 | 13 |
| 705 | Introducing a low-risk breast screening pathway into the NHS Breast Screening Programme: Views from healthcare professionals who are delivering risk-stratified screening. Women's Health, 2021, 17, 174550652110097. | 0.7 | 13 |
| 706 | Womenâ€™s health behaviour change after receiving breast cancer risk estimates with tailored screening and prevention recommendations. BMC Cancer, 2022, 22, 69. | 1.1 | 13 |
| 707 | Ankyloblepharon filiforme adnatum in trisomy 18 Edwards syndrome.. Journal of Medical Genetics, 1990, 27, 720-721. | 1.5 | 12 |
| 708 | Variation in prophylactic surgery decisions. Lancet, The, 2000, 356, 1687. | 6.3 | 12 |
| 709 | High detection rate for BRCA2 mutations in male breast cancer families from North West England. Familial Cancer, 2001, 1, 131-133. | 0.9 | 12 |
| 710 | Diagnosed with breast cancer while on a family history screening programme: an exploratory qualitative study. European Journal of Cancer Care, 2008, 17, 245-252. | 0.7 | 12 |
| 711 | No evidence that GATA3 rs570613 SNP modifies breast cancer risk. Breast Cancer Research and Treatment, 2009, 117, 371-379. | 1.1 | 12 |
| 712 | Mutation and association analysis of GEN1 in breast cancer susceptibility. Breast Cancer Research and Treatment, 2010, 124, 283-288. | 1.1 | 12 |
| 713 | Is multiple <scp>SNP</scp> testing in <scp>BRCA2</scp> and <scp>BRCA1</scp> female carriers ready for use in clinical practice? Results from a large Genetic Centre in the <scp>UK</scp>. Clinical Genetics, 2013, 84, 37-42. | 1.0 | 12 |
| 714 | TheBRCA2polymorphic stop codon: stuff or nonsense?. Journal of Medical Genetics, 2015, 52, 642-645. | 1.5 | 12 |
| 715 | Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. British Journal of Cancer, 2018, 118, 266-276. | 2.9 | 12 |
| 716 | Risk-Reducing Gynecological Surgery in Lynch Syndrome: Results of an International Survey from the Prospective Lynch Syndrome Database. Journal of Clinical Medicine, 2020, 9, 2290. | 1.0 | 12 |
| 717 | Long-Term Evaluation of Women Referred to a Breast Cancer Family History Clinic (Manchester UK) Tj ETQq1 1 0.784314 rgBT /Overlo | 1.7 | 12 |
| 718 | Perceived fatigue in children and young adults with neurofibromatosis type 1. Journal of Paediatrics and Child Health, 2020, 56, 878-883. | 0.4 | 12 |
| 719 | Survival from breast cancer in women with a BRCA2 mutation by treatment. British Journal of Cancer, 2021, 124, 1524-1532. | 2.9 | 12 |
| 720 | Back to the future? Reflections on three phases of education policy reform in Wales and their implications for teachers. Journal of Educational Change, 2022, 23, 371-396. | 2.5 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 721 | Reclassification of clinically-detected sequence variants: Framework for genetic clinicians and clinical scientists by CanVIG-UK (Cancer Variant Interpretation Group UK). Genetics in Medicine, 2022, 24, 1867-1877. | 1.1 | 12 |
| 722 | Genetic evidence for host specificity in the adhesin-encoding genes hxaA of Helicobacter acinonyx, hnaA of H. nemestrinae and hpaA of H. pylori. Gene, 1995, 163, 97-102. | 1.0 | 11 |
| 723 | MSH2 sequence variations and inherited colorectal cancer susceptibility. European Journal of Cancer, 1996, 32, 178. | 1.3 | 11 |
| 724 | A novel deletion within exon 6 of TP53 in a family with Li-Fraumeni-like syndrome, and LOH in a benign lesion from a mutation carrier. Cancer Genetics and Cytogenetics, 1996, 90, 14-16. | 1.0 | 11 |
| 725 | Effect of early American results on patients in a tamoxifen prevention trial (IBIS). Lancet, The, 1998, 352, 1222. | 6.3 | 11 |
| 726 | An evaluation of common breast cancer gene mutations in a population of Ashkenazi Jews.. Journal of Medical Genetics, 1998, 35, 10-12. | 1.5 | 11 |
| 727 | Is It Time to Abandon Microsatellite Instability As a Pre-Screen for Selecting Families for Mutation Testing for Mismatch Repair Genes?. Journal of Clinical Oncology, 2006, 24, 1960-1962. | 0.8 | 11 |
| 728 | Update on genetic predisposition to breast cancer. Expert Review of Anticancer Therapy, 2009, 9, 1103-1113. | 1.1 | 11 |
| 729 | Strategies for endometrial screening in the Lynch syndrome population: a patient acceptability study. Familial Cancer, 2009, 8, 431-439. | 0.9 | 11 |
| 730 | A rapid agonist application system for fast activation of ligand-gated ion channels. Journal of Neuroscience Methods, 2011, 198, 246-254. | 1.3 | 11 |
| 731 | Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. PLoS ONE, 2012, 7, e35706. | 1.1 | 11 |
| 732 | Development of Breast Cancer Choices: a decision support tool for young women with breast cancer deciding whether to have genetic testing for BRCA1/2 mutations. Supportive Care in Cancer, 2019, 27, 297-309. | 1.0 | 11 |
| 733 | An alternative approach to establishing unbiased colorectal cancer risk estimation in Lynch syndrome. Genetics in Medicine, 2019, 21, 2706-2712. | 1.1 | 11 |
| 734 | Sporadic vestibular schwannoma: a molecular testing summary. Journal of Medical Genetics, 2021, 58, 227-233. | 1.5 | 11 |
| 735 | Uptake and efficacy of bilateral risk reducing surgery in unaffected female BRCA1 and BRCA2 carriers. Journal of Medical Genetics, 2022, 59, 133-140. | 1.5 | 11 |
| 736 | Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. European Journal of Cancer, 2021, 148, 124-133. | 1.3 | 11 |
| 737 | No Difference in Penetrance between Truncating and Missense/Aberrant Splicing Pathogenic Variants in MLH1 and MSH2: A Prospective Lynch Syndrome Database Study. Journal of Clinical Medicine, 2021, 10, 2856. | 1.0 | 11 |
| 738 | BRCA and lynch syndrome-associated ovarian cancers behave differently. Gynecologic Oncology Reports, 2017, 22, 108-109. | 0.3 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 739 | Clinical and neuroradiological characterisation of spinal lesions in adults with Neurofibromatosis type 1. Journal of Clinical Neuroscience, 2020, 77, 98-105. | 0.8 | 11 |
| 740 | Evaluation of mammographic surveillance services in women aged 40â€“49 years with a moderate family history of breast cancer: a single-arm cohort study. Health Technology Assessment, 2013, 17, vii-xiv, 1-95. | 1.3 | 11 |
| 741 | ERN GENTURIS clinical practice guidelines for the diagnosis, treatment, management and surveillance of people with schwannomatosis. European Journal of Human Genetics, 2022, 30, 812-817. | 1.4 | 11 |
| 742 | A clinical, genetic and audiological study of patients and families with bilateral acoustic neurofibromatosis. Journal of Laryngology and Otology, 1993, 107, 6-11. | 0.4 | 10 |
| 743 | The pathology of familial breast cancer: Clinical and geneticcounselling implications of breast cancer pathology. Breast Cancer Research, 1999, 1, 48-51. | 2.2 | 10 |
| 744 | Are we ready for targeted early breast cancer detection strategies in women with NF1 aged 30â€“49 years?. American Journal of Medical Genetics, Part A, 2012, 158A, 3054-3055. | 0.7 | 10 |
| 745 | Developing National Guidance on Genetic Testing for Breast Cancer Predisposition: The Role of Economic Evidence?. Genetic Testing and Molecular Biomarkers, 2012, 16, 580-591. | 0.3 | 10 |
| 746 | Common variants modify the age of onset for basal cell carcinomas in Gorlin syndrome. European Journal of Human Genetics, 2015, 23, 708-710. | 1.4 | 10 |
| 747 | Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801. | 1.1 | 10 |
| 748 | High-Grade Glioma is not a Feature of Neurofibromatosis Type 2 in the Unirradiated Patient. Neurosurgery, 2018, 83, 193-196. | 0.6 | 10 |
| 749 | Comparison of a Standard Resolution PET-CT Scanner With an HRRT Brain Scanner for Imaging Small Tumors Within the Head. IEEE Transactions on Radiation and Plasma Medical Sciences, 2019, 3, 434-443. | 2.7 | 10 |
| 750 | Feasibility of Gynaecologist Led Lynch Syndrome Testing in Women with Endometrial Cancer. Journal of Clinical Medicine, 2020, 9, 1842. | 1.0 | 10 |
| 751 | TP53, a gene for colorectal cancer predisposition in the absence of Li-Fraumeni-associated phenotypes. Gut, 2021, 70, 1139-1146. | 6.1 | 10 |
| 752 | Final results of 4-monthly screening in the UK Familial Ovarian Cancer Screening Study (UKFOCSS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 | 0.8 | 10 |
| 753 | Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial. Cancers, 2022, 14, 2716. | 1.7 | 10 |
| 754 | Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women. Genome Medicine, 2022, 14, . | 3.6 | 10 |
| 755 | 2157delG: a frequent mutation in BRCA2 missed by PTT. Journal of Medical Genetics, 2000, 37, 42e-42. | 1.5 | 9 |
| 756 | Psychosocial effects of neurofibromatosis type 2 (Part 1): General effects. Audiological Medicine, 2006, 4, 202-210. | 0.4 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 757 | Extending the Limits of Supertree Methods. Annals of Combinatorics, 2006, 10, 31-51. | 0.3 | 9 |
| 758 | Familial breast cancer: is it time to move from a reactive to a proactive role?. Familial Cancer, 2011, 10, 501-503. | 0.9 | 9 |
| 759 | Are We Ready for Online Tools in Decision Making for BRCA1/2 Mutation Carriers?. Journal of Clinical Oncology, 2012, 30, 471-473. | 0.8 | 9 |
| 760 | Successful radiofrequency ablation of an anterior abdominal wall desmoid in familial adenomatous polyposis. Colorectal Disease, 2013, 15, e160-e163. | 0.7 | 9 |
| 761 | Can multiple SNP testing in BRCA2 and BRCA1 female carriers be used to improve risk prediction models in conjunction with clinical assessment?. BMC Medical Informatics and Decision Making, 2014, 14, 87. | 1.5 | 9 |
| 762 | Validation of a scale for assessing attitudes towards outcomes of genetic cancer testing among primary care providers and breast specialists. PLoS ONE, 2017, 12, e0178447. | 1.1 | 9 |
| 763 | Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2018, 167, 779-785. | 1.1 | 9 |
| 764 | Fanconi anemia with sun-sensitivity caused by a Xeroderma pigmentosum-associated missense mutation in XPF. BMC Medical Genetics, 2018, 19, 7. | 2.1 | 9 |
| 765 | Psychosocial impact of undergoing prostate cancer screening for men with <scp>BRCA</scp>1 or <scp>BRCA</scp>2 mutations. BJU International, 2019, 123, 284-292. | 1.3 | 9 |
| 766 | Analysis in the Prospective Lynch Syndrome Database identifies sarcoma as part of the Lynch syndrome tumor spectrum. International Journal of Cancer, 2021, 148, 512-513. | 2.3 | 9 |
| 767 | Autism Spectrum Disorder Symptom Profile Across the RASopathies. Frontiers in Psychiatry, 2020, 11, 585700. | 1.3 | 9 |
| 768 | Surgical decision making in premenopausal BRCA carriers considering risk-reducing early salpingectomy or salpingo-oophorectomy: a qualitative study. Journal of Medical Genetics, 2021, , jmedgenet-2020-107501. | 1.5 | 9 |
| 769 | A mosaic PIK3CA variant in a young adult with diffuse gastric cancer: case report. European Journal of Human Genetics, 2021, 29, 1354-1358. | 1.4 | 9 |
| 770 | Patient reported outcome measures in a cohort of patients at high risk of breast cancer treated by bilateral risk reducing mastectomy and breast reconstruction. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2022, 75, 69-76. | 0.5 | 9 |
| 771 | Mendelian randomisation study of smoking exposure in relation to breast cancer risk. British Journal of Cancer, 2021, 125, 1135-1145. | 2.9 | 9 |
| 772 | Uptake of bilateral-risk-reducing-mastectomy: Prospective analysis of 7195 women at high-risk of breast cancer. Breast, 2021, 60, 45-52. | 0.9 | 9 |
| 773 | Management of Hereditary Breast Cancer. Disease Markers, 1999, 15, 187-189. | 0.6 | 8 |
| 774 | Risk Estimation as a Decision-Making Tool for Genetic Analysis of the Breast Cancer Susceptibility Genes. Disease Markers, 1999, 15, 53-65. | 0.6 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 775 | Differences AmongHelicobacter pyloriStrains Isolated from Three Different Populations and Demonstrated by Restriction Enzyme Analysis of an Internal Fragment of the Conserved GenehpaA. Helicobacter, 1999, 4, 82-88. | 1.6 | 8 |
| 776 | Clinical and molecular correlates of somatic mosaicism in neurofibromatosis 2. Journal of Medical Genetics, 2000, 37, 542-543. | 1.5 | 8 |
| 777 | Bayesian evaluation of breast cancer screening using data from two studies. Statistics in Medicine, 2003, 22, 1661-1674. | 0.8 | 8 |
| 778 | Nonâ€expression of von Hippelâ€Lindau phenotype in an obligate gene carrier. Clinical Genetics, 1994, 45, 104-106. | 1.0 | 8 |
| 779 | Molecular genetic analysis of exons 1 to 6 of the APC gene in nonâ€polyposis familial colorectal cancer. Clinical Genetics, 1995, 48, 299-303. | 1.0 | 8 |
| 780 | Metachronous colorectal cancer risk in patients with a moderate family history. Colorectal Disease, 2013, 15, 309-316. | 0.7 | 8 |
| 781 | The Genetics of Vestibular Schwannoma. Current Otorhinolaryngology Reports, 2014, 2, 226-234. | 0.2 | 8 |
| 782 | What Is the Malignancy Risk in Neurofibromatosis Type 1?. Journal of Clinical Oncology, 2016, 34, 1967-1969. | 0.8 | 8 |
| 783 | A randomised trial of screening with digital breast tomosynthesis plus conventional digital 2D mammography versus 2D mammography alone in younger higher risk women. European Journal of Radiology, 2017, 94, 133-139. | 1.2 | 8 |
| 784 | â€˜For me it's about not feeling like I'm on a dietâ€™: a thematic analysis of women's experiences of an intermittent energy restricted diet to reduce breast cancer risk. Journal of Human Nutrition and Dietetics, 2018, 31, 773-780. | 1.3 | 8 |
| 785 | Exploring the prediction performance for breast cancer risk based on volumetric mammographic density at different thresholds. Breast Cancer Research, 2018, 20, 49. | 2.2 | 8 |
| 786 | Concern regarding classification of germline TP53 variants as likely pathogenic. Human Mutation, 2019, 40, 828-831. | 1.1 | 8 |
| 787 | A Micro-Costing Study of Screening for Lynch Syndrome-Associated Pathogenic Variants in an Unselected Endometrial Cancer Population: Cheap as NGS Chips?. Frontiers in Oncology, 2019, 9, 61. | 1.3 | 8 |
| 788 | New surveillance guidelines for Li-Fraumeni and hereditary TP53 related cancer syndrome: implications for germline TP53 testing in breast cancer. Familial Cancer, 2021, 20, 1-7. | 0.9 | 8 |
| 789 | Early Adaptation of Colorectal Cancer Cells to the Peritoneal Cavity Is Associated with Activation of â€œStemnessâ€•Programs and Local Inflammation. Clinical Cancer Research, 2021, 27, 1119-1130. | 3.2 | 8 |
| 790 | PTCH2 is not a strong candidate gene for gorlin syndrome predisposition. Familial Cancer, 2022, 21, 343-346. | 0.9 | 8 |
| 791 | Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer. Genetics in Medicine, 2021, 23, 1969-1976. | 1.1 | 8 |
| 792 | Histological and Somatic Mutational Profiles of Mismatch Repair Deficient Endometrial Tumours of Different Aetiologies. Cancers, 2021, 13, 4538. | 1.7 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 793 | C2 neurofibromas in neurofibromatosis type 1: genetic and imaging characteristics. Journal of Neurosurgery: Spine, 2019, 30, 126-132. | 0.9 | 8 |
| 794 | The feasibility of implementing risk stratification into a national breast cancer screening programme: a focus group study investigating the perspectives of healthcare personnel responsible for delivery. BMC Women's Health, 2022, 22, 142. | 0.8 | 8 |
| 795 | The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and metaâ€analysis. International Journal of Cancer, 2022, 151, 1626-1639. | 2.3 | 8 |
| 796 | A computer-based aid for communication between patients with limited English and their clinicians, using symbols and digitised speech. International Journal of Medical Informatics, 2008, 77, 507-517. | 1.6 | 7 |
| 797 | BRCA1, BRCA2 and CHEK2 c.1100 delC mutations in patients with double primaries of the breasts and/or ovaries. Journal of Medical Genetics, 2010, 47, 561-566. | 1.5 | 7 |
| 798 | Development of a Scoring System to Screen for BRCA1/2 Mutations. Methods in Molecular Biology, 2010, 653, 237-247. | 0.4 | 7 |
| 799 | Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. British Journal of Cancer, 2011, 104, 1356-1361. | 2.9 | 7 |
| 800 | Lack of caveolin-1 (P132L) somatic mutations in breast cancer. Breast Cancer Research and Treatment, 2012, 132, 1185-1186. | 1.1 | 7 |
| 801 | Review of radiation therapy services for neurofibromatosis (NF2) patients in England. British Journal of Neurosurgery, 2014, 28, 16-19. | 0.4 | 7 |
| 802 | Is there really an increased risk of early colorectal cancer in women with BRCA1 pathogenic mutations?. Clinical Genetics, 2016, 89, 399-399. | 1.0 | 7 |
| 803 | CNVs affecting cancer predisposing genes (CPGs) detected as incidental findings in routine germline diagnostic chromosomal microarray (CMA) testing. Journal of Medical Genetics, 2018, 55, 89-96. | 1.5 | 7 |
| 804 | Genetic variants of prospectively demonstrated phenocopies in BRCA1/2 kindreds. Hereditary Cancer in Clinical Practice, 2018, 16, 4. | 0.6 | 7 |
| 805 | Final Results of the Prospective FH02 Mammographic Surveillance Study of Women Aged 35â€“39 at Increased Familial Risk of Breast Cancer. EClinicalMedicine, 2019, 7, 39-46. | 3.2 | 7 |
| 806 | A deep intronic SMARCB1 variant associated with schwannomatosis. Clinical Genetics, 2020, 97, 376-377. | 1.0 | 7 |
| 807 | Li-Fraumeni Exploration Consortium Data Coordinating Center: Building an Interactive Web-Based Resource for Collaborative International Cancer Epidemiology Research for a Rare Condition. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 927-935. | 1.1 | 7 |
| 808 | Advances in genetic technologies result in improved diagnosis of mismatch repair deficiency in colorectal and endometrial cancers. Journal of Medical Genetics, 2022, 59, 328-334. | 1.5 | 7 |
| 809 | Identifying challenges in neurofibromatosis: a modified Delphi procedure. European Journal of Human Genetics, 2021, 29, 1625-1633. | 1.4 | 7 |
| 810 | Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women. Breast Cancer Research and Treatment, 2021, 189, 677-687. | 1.1 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 811 | Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Research, 2021, 23, 86. | 2.2 | 7 |
| 812 | From <b><i>BRCA1</i></b> to Polygenic Risk Scores: Mutation-Associated Risks in Breast Cancer-Related Genes. Breast Care, 2021, 16, 202-213. | 0.8 | 7 |
| 813 | Estrogen Deprivation for Breast Cancer Prevention. Recent Results in Cancer Research, 2007, 174, 151-167. | 1.8 | 7 |
| 814 | A clinical, genetic and audiological study of patients and families with unilateral vestibular schwannomas. I. Clinical features of neurofibromatosis in patients with unilateral vestibular schwannomas. Journal of Laryngology and Otology, 1996, 110, 634-40. | 0.4 | 7 |
| 815 | Molecular genetics and endometrial cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2001, 15, 355-363. | 1.4 | 6 |
| 816 | Re: Characterization of Hereditary Nonpolyposis Colorectal Cancer Families From a Population-Based Series of Cases. Journal of the National Cancer Institute, 2001, 93, 716-717. | 3.0 | 6 |
| 817 | Familial colorectal cancer referral to regional genetics departmentâ€”a single centre experience. Familial Cancer, 2007, 6, 81-87. | 0.9 | 6 |
| 818 | Breast cancer prevention: SERMs come of age. Lancet, The, 2013, 381, 1795-1797. | 6.3 | 6 |
| 819 | General Practitioners and Breast Surgeons in France, Germany, Netherlands and the UK show variable breast cancer risk communication profiles. BMC Cancer, 2015, 15, 243. | 1.1 | 6 |
| 820 | MRI Screening in Women With a Personal History of Breast cancer. Journal of the National Cancer Institute, 2016, 108, djv373. | 3.0 | 6 |
| 821 | A Novel <b><i>PTCH1 </i></b>Frameshift Mutation Leading to Nevoid Basal Cell Carcinoma Syndrome. Cytogenetic and Genome Research, 2018, 154, 57-61. | 0.6 | 6 |
| 822 | Gene panel testing for breast cancer should not be used to confirm syndromic gene associations. Npj Genomic Medicine, 2018, 3, 32. | 1.7 | 6 |
| 823 | Lifestyle behaviours and health measures of women at increased risk of breast cancer taking chemoprevention. European Journal of Cancer Prevention, 2019, 28, 500-506. | 0.6 | 6 |
| 824 | [18F]fluorothymidine and [18F]fluorodeoxyglucose PET Imaging Demonstrates Uptake and Differentiates Growth in Neurofibromatosis 2 Related Vestibular Schwannoma. Otology and Neurotology, 2019, 40, 826-835. | 0.7 | 6 |
| 825 | Are women with pathogenic variants in PMS2 and MSH6 really at high lifetime risk of breast cancer?. Genetics in Medicine, 2019, 21, 1878-1879. | 1.1 | 6 |
| 826 | The importance of genetic counseling and screening for people with pathogenic <scp>SMARCE1</scp> variants: A family study. American Journal of Medical Genetics, Part A, 2021, 185, 561-565. | 0.7 | 6 |
| 827 | Prostate Cancer Risk by BRCA2 Genomic Regions. European Urology, 2020, 78, 494-497. | 0.9 | 6 |
| 828 | Germline FFPE inherited cancer panel testing in deceased family members: implications for clinical management of unaffected relatives. European Journal of Human Genetics, 2021, 29, 861-871. | 1.4 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 829 | Volumetric and Area-Based Breast Density Measurement in the Predicting Risk of Cancer at Screening (PROCAS) Study. Lecture Notes in Computer Science, 2012, , 228-235. | 1.0 | 6 |
| 830 | Gliomas in the context of Li-Fraumeni syndrome: An international cohort.. Journal of Clinical Oncology, 2019, 37, 1517-1517. | 0.8 | 6 |
| 831 | The development and evaluation of alternative communication strategies to facilitate interactions with Somali refugees in primary care: a preliminary study. Journal of Innovation in Health Informatics, 2006, 14, 183-189. | 0.9 | 6 |
| 832 | Prevalence and natural history of schwannomas in neurofibromatosis type 2 (NF2): the influence of pathogenic variants. European Journal of Human Genetics, 2022, 30, 458-464. | 1.4 | 6 |
| 833 | Rare germline copy number variants (CNVs) and breast cancer risk. Communications Biology, 2022, 5, 65. | 2.0 | 6 |
| 834 | Cochlear Implantation in Neurofibromatosis Type 2: Experience From the UK Neurofibromatosis Type 2 Service. Otology and Neurotology, 2022, 43, 538-546. | 0.7 | 6 |
| 835 | A Genome-Wide Gene-Based Geneâ€“Environment Interaction Study of Breast Cancer in More than 90,000 Women. Cancer Research Communications, 2022, 2, 211-219. | 0.7 | 6 |
| 836 | Testing a breast cancer prevention and a multiple disease prevention weight loss programme amongst women within the UK NHS breast screening programmeâ€”a randomised feasibility study. Pilot and Feasibility Studies, 2021, 7, 220. | 0.5 | 6 |
| 837 | Development and evaluation of polygenic risk scores for prediction of endometrial cancer risk in European women. Genetics in Medicine, 2022, 24, 1847-1856. | 1.1 | 6 |
| 838 | Molecular genetic tests in surgical management of familial adenomatous polyposis. Lancet, The, 1998, 351, 1131-1132. | 6.3 | 5 |
| 839 | Non-random transmission of mutant alleles to female offspring in BRCA carriers. Journal of Medical Genetics, 2005, 42, e6-e6. | 1.5 | 5 |
| 840 | Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations: More Trouble With Phenocopies. Journal of Clinical Oncology, 2012, 30, 1142-1143. | 0.8 | 5 |
| 841 | Dealing with family history of breast cancer: something new, something old. British Journal of General Practice, 2014, 64, 6-7. | 0.7 | 5 |
| 842 | Multifocality in neurofibromatosis type 2. Neuro-Oncology, 2015, 17, 481-482. | 0.6 | 5 |
| 843 | Evaluation of the relative effectiveness of the 2017 updated Manchester scoring system for predicting BRCA1/2 mutations in a Southeast Asian country. Journal of Medical Genetics, 2018, 55, 344-350. | 1.5 | 5 |
| 844 | Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?. Familial Cancer, 2019, 18, 377-379. | 0.9 | 5 |
| 845 | Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 2019, 9, 12524. | 1.6 | 5 |
| 846 | Uptake of pre-symptomatic testing for BRCA1 and BRCA2 is age, gender, offspring and time-dependent. Journal of Medical Genetics, 2021, 58, 74-78. | 1.5 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 847 | CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. British Journal of Cancer, 2021, 124, 842-854. | 2.9 | 5 |
| 848 | Choose and stay on one out of two paths: distinction between clinical versus research genetic testing to identify cancer predisposition syndromes among patients with cancer. Familial Cancer, 2021, 20, 289-291. | 0.9 | 5 |
| 849 | The Relationship between Body Mass Index and Mammographic Density during a Premenopausal Weight Loss Intervention Study. Cancers, 2021, 13, 3245. | 1.7 | 5 |
| 850 | Pathogenic noncoding variants in the neurofibromatosis and schwannomatosis predisposition genes. Human Mutation, 2021, 42, 1187-1207. | 1.1 | 5 |
| 851 | Gene Panel Testing for Breast Cancer Reveals Differential Effect of Prior BRCA1/2 Probability. Cancers, 2021, 13, 4154. | 1.7 | 5 |
| 852 | Lessons learned from drug trials in neurofibromatosis: A systematic review. European Journal of Medical Genetics, 2021, 64, 104281. | 0.7 | 5 |
| 853 | Automatic density prediction in low dose mammography. , 2020, , . | | 5 |
| 854 | Reâ€evaluation of missense variant classifications in NF2. Human Mutation, 2022, 43, 643-654. | 1.1 | 5 |
| 855 | Does receiving high or low breast cancer risk estimates produce a reduction in subsequent breast cancer screening attendance? Cohort study. Breast, 2022, 64, 47-49. | 0.9 | 5 |
| 856 | Genetic Testing for Breast Cancer Predisposition in 1999: Which Molecular Strategy and which Family Criteria?. Disease Markers, 1999, 15, 67-68. | 0.6 | 4 |
| 857 | Lack of sex-ratio distortion in neurofibromatosis 2. American Journal of Medical Genetics Part A, 2000, 95, 292-292. | 2.4 | 4 |
| 858 | Screening of patients at high risk of colorectal cancer. Colorectal Disease, 2001, 3, 308-311. | 0.7 | 4 |
| 859 | Re: Risk-Reduction Mastectomy: Clinical Issues and Research Needs. Journal of the National Cancer Institute, 2002, 94, 307-307. | 3.0 | 4 |
| 860 | Optimal Selection of Individuals for BRCA Mutation Testing. Journal of Clinical Oncology, 2006, 24, 3311-3311. | 0.8 | 4 |
| 861 | The impact of new screening protocol on individuals at increased risk of colorectal cancer. Colorectal Disease, 2007, 9, 635-640. | 0.7 | 4 |
| 862 | Breast cancer susceptibility variants alter risk in familial ovarian cancer. Familial Cancer, 2010, 9, 503-506. | 0.9 | 4 |
| 863 | High sensitivity for BRCA1/2 mutations in breast/ovarian kindreds: are there still other breast/ovary genes to be discovered?. Breast Cancer Research and Treatment, 2012, 134, 895-897. | 1.1 | 4 |
| 864 | Contralateral risk reducing mastectomy â€“ A national survey of surgeons' practices and perceptions. European Journal of Surgical Oncology, 2013, 39, S64. | 0.5 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 865 | Same task, same observers, different values: the problem with visual assessment of breast density. , 2013, , . | | 4 |
| 866 | Nuclear Deterrence in Asia and the Pacific. Asia and the Pacific Policy Studies, 2014, 1, 91-111. | 0.6 | 4 |
| 867 | Integrated smartcard solutions: do people want one card for all their services?. Transportation Planning and Technology, 2015, 38, 534-551. | 0.9 | 4 |
| 868 | Levels of soya aeroallergens during dockside unloading as measured by personal and static sampling / Razine aeroalergena soje za vrijeme iskrcavanja na luÄkom doku. Arhiv Za Higijenu Rada I Toksikologiju, 2015, 66, 23-29. | 0.4 | 4 |
| 869 | Attitudes to contralateral risk reducing mastectomy among breast and plastic surgeons in England. Annals of the Royal College of Surgeons of England, 2016, 98, 121-127. | 0.3 | 4 |
| 870 | The BRCA1/2 Parent-of-Origin Effect on Breast Cancer Riskâ€"Letter. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 284-284. | 1.1 | 4 |
| 871 | Phase 0 trial investigating the intratumoural concentration and activity of sorafenib in neurofibromatosis type 2. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1184-1187. | 0.9 | 4 |
| 872 | Sporadic implementation of UK familial mammographic surveillance guidelines 15 years after original publication. British Journal of Cancer, 2020, 122, 329-332. | 2.9 | 4 |
| 873 | Beyond Antoni: A Surgeon's Guide to the Vestibular Schwannoma Microenvironment. Journal of Neurological Surgery, Part B: Skull Base, 2022, 83, 001-010. | 0.4 | 4 |
| 874 | Reply to Kratz et al.. European Journal of Human Genetics, 2020, 28, 1483-1485. | 1.4 | 4 |
| 875 | Heritability of mammographic breast density. Quantitative Imaging in Medicine and Surgery, 2020, 10, 2387-2391. | 1.1 | 4 |
| 876 | Long-Term Evaluation of a UK Community Pharmacy-Based Weight Management Service. Pharmacy (Basel, Switzerland), 2020, 8, 22. | 0.6 | 4 |
| 877 | Cost-effectiveness model of renal cell carcinoma (RCC) surveillance in hereditary leiomyomatosis and renal cell carcinoma (HLRCC). Journal of Medical Genetics, 2023, 60, 41-47. | 1.5 | 4 |
| 878 | Talking about Risk, UncertaintieS of Testing IN Genetics (TRUSTING): development and evaluation of an educational programme for healthcare professionals about BRCA1 & BRCA2 testing. British Journal of Cancer, 2022, 127, 1116-1122. | 2.9 | 4 |
| 879 | Cancer risk and tumour spectrum in 172 patients with a germlineSUFUpathogenic variation: a collaborative study of the SIOPE Host Genome Working Group. Journal of Medical Genetics, 2022, 59, 1123-1132. | 1.5 | 4 |
| 880 | Heredity and dysmorphic syndromes in congenital limb deficiencies. Prosthetics and Orthotics International, 1991, 15, 70-77. | 0.5 | 3 |
| 881 | â€˜Should I Take HRT, Doctor?â€™ Hormone Replacement Therapy in Women at Increased Risk of Breast Cancer and in Survivors of the Disease. The Journal of the British Menopause Society, 1995, 1, 9-17. | 1.3 | 3 |
| 882 | Genetic testing for cancer predisposition: need and demand.. Journal of Medical Genetics, 1995, 32, 161-161. | 1.5 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 883 | Risk of subsequent primary cancers in patients with carcinoma of the Ampulla of Vater. British Journal of Cancer, 1997, 76, 1232-1233. | 2.9 | 3 |
| 884 | Germline mutation analysis of the transforming growth factor beta receptor type II (TGFBR2) and E-cadherin (CDH1) genes in early onset and familial colorectal cancer. Journal of Medical Genetics, 2001, 38, 7e-7. | 1.5 | 3 |
| 885 | Neurofibromatosis Type 2 (NF2). , 2011, , 47-70. | | 3 |
| 886 | Ethnopolitical Conflict: When is it Right to Intervene?. Ethnopolitics, 2011, 10, 115-123. | 0.3 | 3 |
| 887 | National survey of patients with Gorlin syndrome highlights poor awareness, multiple treatments and profound psychosocial impact of disease. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 371-373. | 1.3 | 3 |
| 888 | Visual assessment of breast density using Visual Analogue Scales: observer variability, reader attributes and reading time. , 2017, , . | | 3 |
| 889 | RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 58-66. | 1.1 | 3 |
| 890 | Sarcoma in neurofibromatosis 2: case report and review of the literature. Familial Cancer, 2019, 18, 97-100. | 0.9 | 3 |
| 891 | New evidence confirms that reproductive risk factors can be used to stratify breast cancer risks: Implications for a new population screening paradigm. European Journal of Cancer, 2020, 124, 204-206. | 1.3 | 3 |
| 892 | Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation. Hereditary Cancer in Clinical Practice, 2020, 18, 20. | 0.6 | 3 |
| 893 | Infantile fibrosarcoma with TPM3-NTRK1 fusion in a boy with Bloom syndrome. Familial Cancer, 2020, , 1. | 0.9 | 3 |
| 894 | Constitutional de novo deletion CNV encompassing REST predisposes to diffuse hyperplastic perilobar nephroblastomatosis (HPLN). Journal of Medical Genetics, 2021, 58, 581-585. | 1.5 | 3 |
| 895 | Typical 22q11.2 deletion syndrome appears to confer a reduced risk of schwannoma. Genetics in Medicine, 2021, 23, 1779-1782. | 1.1 | 3 |
| 896 | Dominantâ€negative pathogenic variant <scp>BRIP1</scp> c.<scp>1045G</scp>>C is a highâ€risk allele for nonâ€mucinous epithelial ovarian cancer: A caseâ€control study. Clinical Genetics, 2022, 101, 48-54. | 1.0 | 3 |
| 897 | Volumetric and Area-Based Measures of Mammographic Density in Women with and without Cancer. Lecture Notes in Computer Science, 2012, , 589-595. | 1.0 | 3 |
| 898 | Breast surgeons' attitudes towards bilateral risk-reducing mastectomy: A National Survey of American Surgeons.. Journal of Clinical Oncology, 2015, 33, 25-25. | 0.8 | 3 |
| 899 | Screening strategy modification based on personalized breast cancer risk stratification and its implementation in the national guidelines â€“ pilot study. Zdravstveno Varstvo, 2020, 59, 211-218. | 0.6 | 3 |
| 900 | Screening of potential novel candidate genes in schwannomatosis patients. Human Mutation, 2022, 43, 1368-1376. | 1.1 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 901 | Florid oral manifestations in an atypical familial adenomatous polyposis family with late presentation of colorectal polyps. Journal of Oral Pathology and Medicine, 1996, 25, 459-462. | 1.4 | 2 |
| 902 | Management of the contralateral breast in patients with hereditary breast cancer. Breast, 2000, 9, 301-305. | 0.9 | 2 |
| 903 | There may never be a final cure for breast cancer. European Journal of Surgical Oncology, 2001, 27, 338-339. | 0.5 | 2 |
| 904 | Cancer occurrence during follow-up of the CAPP2 study -aspirin use for up to four years significantly reduces Lynch syndrome cancers for up to several years after completion of therapy. Hereditary Cancer in Clinical Practice, 2010, 8, O5. | 0.6 | 2 |
| 905 | Hyperplastic Polyps Are Innocuous Lesions in Hereditary Nonpolyposis Colorectal Cancers. International Journal of Surgical Oncology, 2011, 2011, 1-7. | 0.3 | 2 |
| 906 | Two Out of Three Required. International Journal of Surgical Pathology, 2012, 20, 265-268. | 0.4 | 2 |
| 907 | Comment on the article â€œGermline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebriâ€•by van den Munckhof et al.. Neurogenetics, 2012, 13, 103-104. | 0.7 | 2 |
| 908 | Genetic predisposition to cancer. Medicine, 2012, 40, 29-33. | 0.2 | 2 |
| 909 | Tumour characteristics and survival in familial breast cancer prospectively diagnosed by annual mammography. Breast Cancer Research and Treatment, 2015, 152, 87-94. | 1.1 | 2 |
| 910 | Local mammographic density as a predictor of breast cancer. Proceedings of SPIE, 2015, , . | 0.8 | 2 |
| 911 | No strong evidence for increased risk of breast cancer 8â€“26 years after multiple mammograms in their 30s in females at moderate and high familial risk. British Journal of Radiology, 2016, 89, 20150960. | 1.0 | 2 |
| 912 | Genetic predisposition to cancer. Medicine, 2016, 44, 65-68. | 0.2 | 2 |
| 913 | Cranial irradiation in childhood mimicking neurofibromatosis type II. American Journal of Medical Genetics, Part A, 2017, 173, 1635-1639. | 0.7 | 2 |
| 914 | Neurofibromatosis type 2: Multiple intraâ€dermal tumors in a toddler. American Journal of Medical Genetics, Part A, 2017, 173, 1447-1449. | 0.7 | 2 |
| 915 | Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scores. Familial Cancer, 2017, 16, 173-179. | 0.9 | 2 |
| 916 | Findings Linking Mismatch Repair Mutation With Age at Endometrial and Ovarian Cancer Onset in Lynch Syndromeâ€”Reply. JAMA Oncology, 2018, 4, 890. | 3.4 | 2 |
| 917 | Multiple primary malignancies associated with a germline SMARCB1 pathogenic variant. Familial Cancer, 2019, 18, 445-449. | 0.9 | 2 |
| 918 | Neurosurgical contribution within a complex NF1 supraregional service. Clinical Neurology and Neurosurgery, 2019, 180, 18-24. | 0.6 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 919 | Rapid reversal of clinical downâ€classification of a BRCA1 splicing variant avoiding psychological harm. Clinical Genetics, 2019, 95, 532-533. | 1.0 | 2 |
| 920 | Challenging the believed proportion of ovarian cancer attributable to BRCA2 versus BRCA1 pathogenic variants. European Journal of Cancer, 2020, 124, 88-90. | 1.3 | 2 |
| 921 | Regarding â€œNeuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade gliomaâ€. Neuro-Oncology Practice, 2020, 7, 572-573. | 1.0 | 2 |
| 922 | Neurofibromatosis type 2 discordance in monozygous twins. Familial Cancer, 2020, 19, 37-40. | 0.9 | 2 |
| 923 | Is Breast Cancer Risk Associated with Menopausal Hormone Therapy Modified by Current or Early Adulthood BMI or Age of First Pregnancy?. Cancers, 2021, 13, 2710. | 1.7 | 2 |
| 924 | Microscopy and chemical analyses reveal flavone-based woolly fibres extrude from micron-sized holes in glandular trichomes of Dionysia tapetodes. BMC Plant Biology, 2021, 21, 258. | 1.6 | 2 |
| 925 | The ethics of testing for cancer-predisposition genes. , 1996, , 383-393. | | 2 |
| 926 | Risk of contralateral breast cancer amongst BRCA1/2 mutation carriers. Translational Cancer Research, 2016, 5, S1066-S1069. | 0.4 | 2 |
| 927 | BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?. British Journal of Cancer, 2022, 127, 163-167. | 2.9 | 2 |
| 928 | Comparison of the frequency of lossâ€ofâ€function LZTR1 variants between schwannomatosis patients and the general population. Human Mutation, 2022, 43, 919-927. | 1.1 | 2 |
| 929 | Risk perception and disease knowledge in attendees of a community-based lung cancer screening programme. Lung Cancer, 2022, 168, 1-9. | 0.9 | 2 |
| 930 | Solving the genetic aetiology of hereditary gastrointestinal tumour syndromesâ€“ a collaborative multicentre endeavour within the project Solve-RD. European Journal of Medical Genetics, 2022, 65, 104475. | 0.7 | 2 |
| 931 | Genetic markers for breast cancer. Breast, 1996, 5, 374-376. | 0.9 | 1 |
| 932 | Neurofibromatosis type 2. , 2004, , 50-59. | | 1 |
| 933 | Family history of breast cancer. BMJ: British Medical Journal, 2005, 330, 730.1. | 2.4 | 1 |
| 934 | Contralateral breast cancer risk in BRCA1/2-positive families needs to be adjusted for phenocopy rates particularly in second-degree untested relatives. Breast Cancer Research, 2013, 15, 401. | 2.2 | 1 |
| 935 | Contralateral breast cancer in high-risk patients: Identification of risk factors to guide recommendations for contralateral prophylactic mastectomy â€“ A 30-year experience. European Journal of Surgical Oncology, 2013, 39, 520. | 0.5 | 1 |
| 936 | Mastectomies of healthy, contralateral breasts in patients with breast cancer. British Journal of Hospital Medicine (London, England: 2005), 2013, 74, 486-487. | 0.2 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 937 | Can manipulation of splicing offer gene therapy possibilities to those with tumour-prone disorders?. European Journal of Human Genetics, 2013, 21, 701-702. | 1.4 | 1 |
| 938 | BCRT response to Moller. Breast Cancer Research and Treatment, 2014, 148, 693-693. | 1.1 | 1 |
| 939 | Contralateral risk reducing mastectomy â€“ The Manchester experience. European Journal of Surgical Oncology, 2014, 40, 618. | 0.5 | 1 |
| 940 | Threshold for genetic testing in women with breast cancer needs to be determined. BMJ, The, 2014, 348, g1863-g1863. | 3.0 | 1 |
| 941 | 20. Breast surgeons' attitudes towards bilateral risk reducing mastectomy â€“ A comparison between the UK, the US, France and Germany. European Journal of Surgical Oncology, 2015, 41, S23. | 0.5 | 1 |
| 942 | Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. Obstetrical and Gynecological Survey, 2017, 72, 338-340. | 0.2 | 1 |
| 943 | Population-based testing of non-mucinous epithelial ovarian cancer in Scotland. BJOG: an International Journal of Obstetrics and Gynaecology, 2018, 125, 1459-1459. | 1.1 | 1 |
| 944 | Penetrance estimates for BRCA1, BRCA2 (also applied to Lynch syndrome) based on presymptomatic testing: a new unbiased method to assess risk?. Journal of Medical Genetics, 2018, 55, 442-448. | 1.5 | 1 |
| 945 | Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture. EBioMedicine, 2018, 36, 508-516. | 2.7 | 1 |
| 946 | NFM-04. INITIAL MANAGEMENT STRATEGY AS A DISCRIMINATOR OF VISUAL OUTCOME IN CHILDREN PRESENTING WITH NEUROFIBROMATOSIS TYPE 1 AND OPTIC PATHWAY GLIOMA - RESULTS FROM A SOCIÃ‰TÃ‰ INTERNATIONALE Dâ€™ONCOLOGIE PÃ‰DIATRIQUE EUROPE (SIOPE) CLINICAL TRIALS WORKSHOP. Neuro-Oncology, 2018, 20, i143-i143. | 0.6 | 1 |
| 947 | Age at diagnosis of cancer in 185delAG BRCA1 mutation carriers of diverse ethnicities: tentative evidence for modifier factors. Familial Cancer, 2020, 20, 189-194. | 0.9 | 1 |
| 948 | Response to Benusiglio et al.. Genetics in Medicine, 2020, 22, 1424-1425. | 1.1 | 1 |
| 949 | Comment on: SMARCB1 Gene Mutation Predisposes to Earlier Development of Glioblastoma: A Case Report of Familial GBM. Journal of Neuropathology and Experimental Neurology, 2021, 80, 289-290. | 0.9 | 1 |
| 950 | Extended gene panel testing in lobular breast cancer. Familial Cancer, 2022, 21, 129-136. | 0.9 | 1 |
| 951 | Optical coherence tomography significance in managing complex neurofibromatosis 2-related papilledema: Report of a case. JRSM Open, 2021, 12, 205427042098145. | 0.2 | 1 |
| 952 | Effect of WBC BRCA1 promoter methylation on ovarian cancer risk.. Journal of Clinical Oncology, 2011, 29, 5029-5029. | 0.8 | 1 |
| 953 | Ethnic Variation in Volumetric Breast Density. Lecture Notes in Computer Science, 2012, , 127-133. | 1.0 | 1 |
| 954 | Mammographic Density Over Time in Women With and Without Breast Cancer. Lecture Notes in Computer Science, 2016, , 291-298. | 1.0 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 955 | Earlier decisions on breast and ovarian surgery reduce cancer in women at high risk. BMJ, The, 2022, 376, o258. | 3.0 | 1 |
| 956 | Space Infections of the Head and Neck - The "New" Clinical Picture. Journal of the Royal Army Medical Corps, 1991, 137, 35-37. | 0.8 | 0 |
| 957 | No useful role for fine needle aspiration as a marker for familial breast cancer. Breast, 2000, 9, 218-219. | 0.9 | 0 |
| 958 | Hereditary cancer. Lancet Oncology, The, 2000, 1, 12. | 5.1 | 0 |
| 959 | Familial Ovarian Cancer Screening. Journal of Clinical Oncology, 2006, 24, e11-e11. | 0.8 | 0 |
| 960 | Evidence for a colorectal cancer susceptibility locus on chromosome 3q21â€“q24 from a high-density SNP genome-wide linkage scan. Human Molecular Genetics, 2006, 15, 3592-3592. | 1.4 | 0 |
| 961 | Genetic predisposition to cancer. Medicine, 2008, 36, 50-54. | 0.2 | 0 |
| 962 | Isolated unilateral vestibular schwannomas do not harborHRASmutations. American Journal of Medical Genetics, Part A, 2010, 152A, 1586-1587. | 0.7 | 0 |
| 963 | Detection and management of women at increased risk of breast cancer. Clinical Practice (London,) Tj ETQq1 1 0.784314 rgBT /Overl | 0.1 | 0 |
| 964 | Prophylactic mastectomy and breast cancer. British Journal of Hospital Medicine (London, England:) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 | 0.2 | 0 |
| 965 | Key genetic considerations in the management of suspected hereditary colorectal cancer. Colorectal Cancer, 2013, 2, 31-41. | 0.8 | 0 |
| 966 | Current Concepts in Management of Vestibular Schwannomas in Neurofibromatosis Type 2. Current Otorhinolaryngology Reports, 2014, 2, 248-255. | 0.2 | 0 |
| 967 | The Fragile X Protein binds mRNA s involved in cancer progression and modulates metastasis formation. EMBO Molecular Medicine, 2014, 6, 567-568. | 3.3 | 0 |
| 968 | Response to Santoro et al. Breast Cancer Research and Treatment, 2014, 147, 689-689. | 1.1 | 0 |
| 969 | Pathogenesis and management of type 2 neurofibromatosis. Expert Opinion on Orphan Drugs, 2015, 3, 281-292. | 0.5 | 0 |
| 970 | Finding Common Ground: Negotiating Across Cultures on Peace and Security Issues. Global Policy, 2016, 7, 458-463. | 1.0 | 0 |
| 971 | Biochemical Insights into Merlin/NF2 Pathophysiology and Biologically Targeted Therapies in Childhood NF2 and Related Forms. Journal of Pediatric Biochemistry, 2016, 05, 120-130. | 0.2 | 0 |
| 972 | The impact of using weight estimated from mammographic images vs. self-reported weight on breast cancer risk calculation. Proceedings of SPIE, 2017, 10134, . | 0.8 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 973 | Does the prediction of breast cancer improve using a combination of mammographic density measures compared to individual measures alone?. Proceedings of SPIE, 2017, , . | 0.8 | 0 |
| 974 | O15 Bioaccessibility of organosulphur compounds from Allium sativum. Biochemical Pharmacology, 2017, 139, 114. | 2.0 | 0 |
| 975 | 353 C2 Segmental Neurofibromas in Patients with Neurofibromatosis Type 1. Neurosurgery, 2017, 64, 280-281. | 0.6 | 0 |
| 976 | Low Lifetime Risk of Contralateral Breast Cancer in a Middleâ€Income Asian Country: Evidence to Guide Postâ€treatment Surveillance. World Journal of Surgery, 2018, 42, 1270-1277. | 0.8 | 0 |
| 977 | Cancer surveillance, obesity, and potential bias. Lancet Public Health, The, 2019, 4, e218. | 4.7 | 0 |
| 978 | Identifying modifiable and non-modifiable risk factors of epithelial ovarian cancerâ€”can we get it better?. Gynecology and Pelvic Medicine, 2019, 2, 21-21. | 0.1 | 0 |
| 979 | Association Between Invasive Lobular Breast Cancer and Mutations in the Mismatch Repair Gene MSH6. JAMA Oncology, 2019, 5, 119. | 3.4 | 0 |
| 980 | Genetic predisposition to cancer. Medicine, 2020, 48, 138-143. | 0.2 | 0 |
| 981 | Future Research Suggestions for Multigene Testing in Unselected Populationsâ€”Reply. JAMA Oncology, 2020, 6, 785. | 3.4 | 0 |
| 982 | Global burden of childhood and adolescent cancer. Chinese Clinical Oncology, 2020, 9, 56-56. | 0.4 | 0 |
| 983 | Translabyrinthine resection of NF2 associated vestibular schwannoma with cochlear implant insertion. Neurosurgical Focus Video, 2021, 5, V14. | 0.1 | 0 |
| 984 | Genetic and cytogenetic studies in inherited cancer: Li-Fraumeni syndrome. , 2000, , 245-255. | | 0 |
| 985 | Polymorphisms of the aromatase gene (CYP19A1) and benefit of aromatase inhibitors (AIs) in metastatic breast cancer (mBC) patients.. Journal of Clinical Oncology, 2011, 29, 608-608. | 0.8 | 0 |
| 986 | Cranial Meningioma in Neurofibromatosis Type 2 Patients: Role of Mutations. Tumors of the Central Nervous System, 2014, , 271-276. | 0.1 | 0 |
| 987 | Abstract A35: SMARCE1 mutations cause inherited multiple spinal meningiomas. , 2013, , . | | 0 |
| 988 | The genetics of breast cancer, risk-reducing surgery and prevention. , 2014, , 127-145. | | 0 |
| 989 | Small Bowel Cancer in the UK. American Journal of Gastroenterology, 2014, 109, S116-S117. | 0.2 | 0 |
| 990 | Evaluating Transport Technologies for Mitigating the Impact of Emergency Events: Findings from the SAVE ME Project. International Journal of Transportation, 2014, 2, 73-94. | 0.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 991 | Abstract P5-12-01: Predicting the effect of tamoxifen on the breast: Change in measures of breast density, serum markers and SNPs. , 2015, , . | | 0 |
| 992 | Challenges and Opportunities in the Implementation of Risk-Based Screening for Breast Cancer. , 2016, , 165-187. | | 0 |
| 993 | Should We Adjust Visually Assessed Mammographic Density for Observer Variability?. Lecture Notes in Computer Science, 2016, , 540-547. | 1.0 | 0 |
| 994 | Variations in Breast Density and Mammographic Risk Factors in Different Ethnic Groups. Lecture Notes in Computer Science, 2016, , 510-517. | 1.0 | 0 |
| 995 | Reader performance in visual assessment of breast density using visual analogue scales: are some readers more predictive of breast cancer?. , 2018, , . | | 0 |
| 996 | Risk-reducing mastectomy rates in the US: A closer examination of the Angelina Jolie effect.. Journal of Clinical Oncology, 2018, 36, e13557-e13557. | 0.8 | 0 |
| 997 | Using a convolutional neural network to predict readers' estimates of mammographic density for breast cancer risk assessment. , 2018, , . | | 0 |
| 998 | 505â€...Attitudes towards risk reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study. , 2020, , . | | 0 |
| 999 | 507â€...Surgical decision making in premenopausal brca carriers considering risk reducing early-salpingectomy or salpingo-oophorectomy: a qualitative study. , 2020, , . | | 0 |
| 1000 | Naevoid basal cell carcinoma syndrome. , 2022, , 449-452. | | 0 |
| 1001 | Inherited Cancer Genetic Epidemiology to Improve Precision Medicine. Journal of Clinical Medicine, 2022, 11, 879. | 1.0 | 0 |
| 1002 | Abstract P1-10-01: Results from the breast cancer - anti progestin prevention study 1 (BC-APPS1) trial - a novel approach in breast cancer prevention. Cancer Research, 2022, 82, P1-10-01-P1-10-01. | 0.4 | 0 |
| 1003 | Neuroanatomical correlates of working memory performance in Neurofibromatosis 1. Cerebral Cortex Communications, 2022, 3, . | 0.7 | 0 |
| 1004 | Predicting the likelihood of aBRCA1/2pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer. Journal of Clinical Pathology, 2023, 76, 684-689. | 1.0 | 0 |